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ABSTRACT
Atrial natriuretic peptide (ANP) has previously been show n to bind to 
specific ANP receptors and increase intracellular cGMP levels in purified 
rat cardiac sarcolemmal membranes. Experiments described in this thesis 
w ere perform ed to investigate the binding characteristics of ANP in 
bovine ventricular sarcolemmal membranes and in plasm a membranes 
isolated  from  the liver of hypertension-resistant and hypertension- 
sensitive Dahl rats fed on two dietary salt regimes one of 0.8% NaCl and 
the other 8 % NaCl. Additional experiments utilising ANP analogues in 
rad io -recep to r assays and radio-receptor crosslinking assays were 
perfo rm ed  to determ ine the precise natu re  of the ANP receptor 
population present in these membrane preparations.
In bovine ventricular cardiac sarcolemm al m em branes, ANP bound 
specifically to one class of ANP receptor with a K j of approximately 44 pM 
and a Bmax of approximately 49 fm ol/m g protein. ANP produced a 1.8-fold 
stim ulation of m anganese-dependent guanylate cyclase activity with an 
EC50 value of approximately 1 nM. Receptor binding using the des-ANP 
analogue indicated the predom inant presence of the ANP-B receptor 
subtype. Radioreceptor crosslinking experiments d id  not entirely agree 
w ith  these experiments. Radio-receptor crosslinking indicated the 
presence of two ANP receptors one of 60 kDa and one of 120 kDa, 
equivalent to the molecular weights of ANP receptors found in other 
tissues. Collectively these experiments indicate that bovine ventricular 
sarcolemmal membranes possess ANP receptors, at least a proportion of 
which are coupled to guanylate cyclase (ANP-B receptors).
In plasm a m em branes from the liver of Dahl-Resistant (Dahl-R) and 
Dahl-Sensitive (Dahl-S) rats, ANP bound specifically to one class of ANP 
receptor w ith Kd values ranging from 245 to 288 pM  and Bmax values 
ranging from 104 to 217 fm ol/m g protein. ANP produced a 3.8 to 6.15-fold 
stim ulation of m anganese-dependent guanylate cyclase activity w ith an 
EC50 values ranging from 2.3 to 7.4 nM, dependent on the strain of Dahl 
rat and the dietary salt regime used. In liver membranes isolated from 
rats sensitive to salt-induced hypertension results indicated increases in 
Bmax w ith no change in Kd for ANP binding to receptors and higher basal 
and ANP-stimulated guanylate cyclase levels. Receptor binding using the 
des-ANP analogue indicated the presence of 13-33% ANP-C receptors with 
a majority of ANP-B receptors in plasma membranes isolated from the 
liver of Dahl-R and Dahl-S rats. However, radio-receptor crosslinking 
experim ents w ere unable to support these results. Collectively these 
experiments indicate that in plasma membranes isolated from the liver of 
Dahl-R and Dahl-S rats possess ANP receptors, at least a majority of which 
are coupled to guanylate cyclase (ANP-B receptors) and that sensitivity to 
hypertension induced by a high salt dietary regime increases the density of 
ANP receptors coupled to guanylate cyclase.
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GROUP
ECsocGMP
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a 3.1612.04 245180
b 2.3310.47 258118
c 2.910.71 285132
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CHAPTER 1
INTRODUCTION
1.1 ATRIAL NATRIURETIC PEPTIDE
1.1.1 History of ANP
Atrial natriuretic factor (ANF) is stored primarily in specific granules of 
atrial myocytes and plays a key m odulatory role in the regulation of 
extracellular fluid volume and blood pressure, (DeBold et ah 1981). The 
presence of specific granules, in the atria, was first described by Kisch in 
(1956). In the same year, H enry and co-workers (Henry et ah 1956), 
reported that distension of the left atrium  altered u rinary  excretion, 
however these two separate observations were not linked for over two 
decades. For many years the atrial specific granules (Jamieson & Palade 
1964) w ere though t to serve as storage sites for endogenous 
catecholamines in the heart, (Palade 1961; De Bold & Bencosme 1973). By 
the seventies Marie et al. (1976) and De Bold (1979), dem onstrated that 
water loading and increasing sodium  levels caused a significant decrease 
in the num ber of atrial cell granules. In 1981, De Bold et al. (1981) 
dem onstrated that injection of atrial, but not ventricular tissue extracts, 
into anaesthetised rats caused a m arked increase in urinary sodium  and 
water excretion. The substance in these extracts was given the name atrial 
natriuretic factor (ANF). Confirmation that these atrial specific granules 
w ere  the  likely storage sites for ANF came in 1982, w ith  the 
dem onstration that partially purified granules showed natriuretic and 
diuretic properties (De Bold 1982; Garcia et al. 1982).
De Bold's work led to the characterisation and sequencing of a closely 
related family of peptides from the atria, (see section 1.1.4). They were 
given various names; atriopeptins, auriculins, cardionatrins and ANF’s. 
ANF is now known to be a peptide and is generally referred to as Atrial 
Natriuretic Peptide (ANP).
Since its discovery almost 10 years ago, many studies have been carried 
ou t on the biochemistry and physiology of ANP both in vitro and in 
vivo. The information obtained from  these studies is summarised in the 
next sections and includes a detailed description of the synthesis and 
structure of ANP, ANP receptors and endogenous guanylate cyclase 
activity, mechanisms controlling the release of ANP, some physiological 
and pharmacological actions of ANP and the role played by ANP in 
hypertension.
1.1.2 ANP Gene Structure
Using complementary DNA (cDNA) probes specific for ANP, the genomic 
DNA encoding prepro-ANP has been identified in man, (Greenberg et al. 
1984; Nem er et al. 1984) mouse, (Seidman et al. 1984) rat, (Argentin et al. 
1985) and ox, (Vlasuk et al. 1986). The gene sequence is highly conserved 
between species and possibly exists as a single copy, (Seidman et al. 1984; 
Argentin et al. 1985; Oikawa et al. 1984). Nucleotide sequence analysis of 
these genes shows that human, rat, m ouse and ox have 3 coding regions 
(exons) and 2 intervening sequences (introns). The first exon encodes an 
untranslated  5' sequence, the ATG initiation codon, a signal peptide 
sequence of 24 amino acids and the first 17 amino acids of proANP. The 
second exon encodes the remaining amino acid sequence of proANP with 
the exception of 1 amino acid in hum an and 3 amino acids in rat, mouse
and ox. These C-terminal amino acids are encoded in the third exon 
which also contains the stop codon and an untranslated 3' sequence, (see 
fig. 1.1).
The second intron of the ra t and  the hum an ANP gene contains a 
consensus sequence for a potential glucocorticoid receptor binding site, 
(Greenberg et ah 1984; Argentin et ah 1985). This raises the possibility that 
ANP gene expression may be regulated by glucocorticoids. Gardner et ah 
(1986, 1988) and Nem er et ah (1987) support this w ith  evidence that 
glucocorticoids produce a 2-3 fold increase in atrial ANP-spedfic mRNA 
levels in the rat.
1.1.3 Gene Expression of ANP
1.1.3.1 ANP Gene Expression in  the Heart
In atrial tissues, ANP-specific mRNA represents approxim ately 1-3% of 
the total poly(A)+ RNA, (Bloch et ah 1987). Nakayama et ah (1984) studied 
the regulation of gene transcription and showed that ANP mRNA levels 
in  w ater deprived rats decreased by approxim ately 50% after 2 days 
dehydration and by 75% after 4 days dehydration, the latter was in 
conjunction with a 60% depletion of total atrial mRNA. Takayanagi et ah
(1985) also observed 70% decreases in the level of ANP-specific mRNA in 
w ater deprived animals (5 days) w ith a concurrent 50% decrease in 
plasm a ANP concentration and a 200% increase in atrial ANP content. 
This was in agreement w ith Marie et ah (1976) and De Bold et ah (1979), 
w ho dem onstrated that induction  of w ater deprivation and sodium  
deficiency caused significant increases in the num ber of atrial granules. 
Takayanagi et ah (1985) reported that ANP-spedfic mRNA concentrations 
decreased in rats on a low salt diet, but that the concentrations in animals
Figure 1.1
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on a high salt diet d id  no t differ from the control animals. Recently 
however, Hong et al. (1990) showed that short term  water deprivation in 
rats for 2 and 4 days caused an increase in ANP-specific mRNA by 2.1 and 
1.6-fold respectively, w ith a slight decrease at 6 days of 0.38-fold. They also 
reported increased ANP-specific mRNA gene expression with short term, 
salt loading (0.9% NaCl in drinking water) for 2, 4 and 6 days with 2.4, 2.8 
and 2-fold increases respectively. These results all suggest that body fluid 
and sodium balance are associated with ANP gene expression in the 
heart, although there still exists some controversy as to the precise nature 
of this relationship.
1.1.3.2 ANP Gene Expression in  other tissues
Although the major source of plasma ANP is the secretory vesicles of the 
atria, cDNA probes have identified extra-atrial expression of ANP 
(Gardner et al. 1985). ANP-specific mRNA has been detected in the 
ventricles, lung, p itu ita ry  g land and the hypothalam us of the rat, 
although in concentrations 100-250 fold less than those found in atria. 
Expression of the ANP gene in brain (Morii et al. 1985; Saper et al. 1985), 
lung (Sakamoto et al. 1985b) and kidney (Sakamoto et al. 1985a), has also 
been dem onstrated by bo th  im m unohistochem ical and  biochemical 
analayses. The precise physiological function of ANP in these extra-atrial 
tissues remains unknown. Gutkowska & Nem er (1989) provides a full 
sum m ary of structure, expression and function of ANP in extra-atrial 
tissues. Gardner et al. (1987), detected ANP-specific mRNA in distal 
thoracic aorta at levels less than the aortic arch which were in turn much 
less than that found in the atria. They also visualised ANP using 
immunochemistry in these tissues. Gardner et al. (1987) speculated that 
ANP may play an im portant role as a paracrine/autocrine factor. Gardner
et al, (1985), Nemer et al, (1986) and Takayanagi et al. (1987a) suggested 
that the presence of ANP containing cells in the ventricle may allow for 
secretion of ANP into the circulation, in addition to ANP secretion from 
the atria. Interestingly, the levels of ANP and ANP-specific mRNA in 
the ventricles can be altered under certain conditions. Takayanagi et al. 
(1987a) observed ventricular ANP levels 3-fold higher in spontaneously 
hypertensive rats com pared to norm otensive controls. Lattion et al.
(1986) and N em er et al. (1987) show ed a preferen tial increase in 
ventricular ANP-specific mRNA (4 to 11-fold) over atrial ANP-specific 
mRNA (1.5 to 3.3-fold) w ith  volum e overload and  glucocorticoid 
adm inistration.
1.1.4 Secretion and Processing of ANF
The amino acid sequences of a num ber of rat atrial peptides possessing 
natriuretic and diuretic properties were published sim ultaneously by 
various laboratories; (Flynn et al. 1983; Currie et al. 1984a; Geller et al. 
1984; Misono et al. 1984a; Misono et al. 1984b; Seidah et al 1984; Kangawa 
et al. 1985a; Kangawa et al. 1985b and Atlas et al. 1984). These reports 
indicated the presence of a variety of peptides ranging from 19-35 amino 
acids in length. These initial studies indicated significant similarities 
between the different peptides. Kangawa & Matsuo (1984) and Thibault et 
al. (1984) carried out similar work with human atrial extracts and isolated 
an ANP sequence which only differed from rat atrial ANP sequences in 
possessing a m ethionine residue in place of an isoleucine residue at 
position 12, of the m ature peptide (see fig. 1.2). Essentially all of the 
pep tides isolated w ere extended or truncated  versions of the same 
peptide, which contained a basic 17 amino acid intramolecular sulphide 
loop sequence. Larger molecular weight peptides w ere shown to be
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quickly converted to low molecular weight forms. Trippodo et al. (1984b), 
showed this by mixing higher molecular weight forms with crude atrial 
extracts. Currie et al. (1984b) also showed this by gentle proteolysis of 
higher molecular weight forms. These observations strongly supported 
the idea that low molecular weight forms appeared to be derived from the 
carboxy-terminal of a higher molecular weight precursor protein.
The prim ary structure of the ANP precursor was determined from  the 
DNA sequence of ANP cDNA clones by location of the reading frame 
containing the C-terminal ANP peptides and following its N-terminus to 
the ATG initiation codon and a classic signal peptide sequence, (Perlman 
& Halverson 1983). (Most secretory proteins possess an N -term inal 
sequence of 16-30 hydrophobic amino acids (the signal peptide sequence) 
that is thought to initiate transport across the endoplasmic reticulum  
(Darnell et al. 1986)). Translation of a prepro-ANP cDNA clone in the rat 
revealed a 152 amino acid sequence of preproANP (Maki et al. 1984), of 
which the first 24 amino ad d s are the signal sequence. In the hum an 
prepro-ANP was found to be 151 amino acids in length (Oikawa et al. 
1984), of which the first 25 residues are the signal sequence. ANP is the 
final 28 amino acids, (known as a-ANP) at the carboxy-terminal of the 
prepro-ANP sequence. Hum an prepro-ANP shares 80% homology w ith 
the ra t peptide, w ith the greatest similarity at the carboxy-terminal of 
ANP, where there is only one amino acid of a difference.
Pro-ANP, (known as y-ANP) in the rat, form ed after signal peptide 
processing and removal of the COOH-terminal arginine dipeptide of rat 
preproA N P, is 126 am ino acids in length. Pro-ANP in the hum an, 
formed after signal peptide processing of hum an preproANP is also 126
6 "
amino acids in length. A 30 amino acid N-term inus sequence of pro- 
ANP is hom ologous to the N -term inus sequence of a peptide w ith  
vasodilator/ properties, cardiodilatin, previously extracted from porcine 
atria (Frossman et al 1983; 1984).
In plasma, a-A NP has been identified (Miyata et al 1985) as the m ain 
circulatory form (Glembotski et al. 1985; Im ada et al. 1985), whereas in the 
hum an atrium , the m ain storage form  has been identified as y-A N P, 
although this form has also been found in low  concentrations in the 
circulation (Kangawa et al. 1985). The rat atrium  also contains y-ANP as 
its major storage form (Kangawa et ah 1984). Conversion of the high 
molecular weight precursor to the 28 amino acid active peptide either 
takes place immediately before, or m ore likely immediately after secretion 
from the atrial cardiocytes. The mechanism of this conversion has not yet 
been elucidated. However a specific extracellular atrial protease has been 
im plicated in the final processing (Rugg et ah 1988; Johnson & Foster
1990).
Another circulatory related but distinct form of ANP has been identified 
in hum an plasma, known as p-ANP (56 am ino adds) (Kangawa et ah 
1984; 1985). p-ANP is an antiparallel dimeric form of a-ANP (Kangawa & 
Matsuo 1984; Nakao et ah 1984). Kangawa et ah (1985) showed that a-A N P 
d id  not undergo d im érisation  to p-A N P w ith  the experim ental 
purification conditions utilised. In addition , Kangawa et ah (1984) 
observed that p-ANP was endogenous to the atria although the process in 
which dim érisation takes place in vivo rem ains unknown. Itoh et ah 
(1988) reported that P-ANP is converted to a-A N P in the hum an
circulation. The natriuretic and diuretic properties of P-ANP are slower 
acting than a-ANP, though p-ANP has a more potent and lasting action.
The presence of both y-ANP and a-A N P have been reported  in rat 
ventricle, w ith a-ANP, (Inagami et ah 1987) and y-ANP (Miyata ef al. 1986) 
being reported as the predom inant form, respectively. Tanaka et al, (1984) 
show ed that ANP in the brain  consists m ainly of a -A N P  and  an 
intermediate form (less than 28 but more than 25 amino adds). Imada et 
al. (1985) also reported the existence of several ANP like peptides of 28 
amino acids or less in the brain. This finding has been supported by other 
workers including, Morii et al. (1985), Glembotski et al. (1985) and Shiono 
et al. (1986).
1.1.5 O ther related Natriuretic Peptides
In addition to P-ANP and y-ANP, (see section 1.1.4) a related peptide, 
initially isolated from porcine brain (Sudoh et al. 1988a; 1988b) and then 
from porcine heart (Kambayaski et al, 1990) has been shown to possess 
natriuretic and diuretic properties similar to that of ANP. This peptide 
has been nam ed, brain natriuretic peptide (BNP). BNP comprises 26 
am ino acids and shares 60% hom ology w ith ANP. Iso-rat atrial 
natriuretic peptide, (iso-rANP), another related natriuretic peptide has 
been identified from rat atria (Flynn et al. 1989; Jennings & Flynn 1989 
and  1990). Iso-rat ANP is com posed of 45 amino acids and  its 
concentration in the rat atria is less than 1% of that of ANP (Flynn et al. 
1989). Hom ology betw een ANP, BNP and iso-rANP resides m ainly 
within the loop of amino acids formed by the intra-disulphide bond, with 
less homology at the amino and carboxy-termini. More recently another 
peptide known as CNP (C-type natriuretic peptide) has been isolated from
porcine brain, (Sudoh et al. 1990). CNP has an amino acid sequence 
hom ologous to both ANP and BNP and also contains an intramolecular 
disulphide bond. It is however unique in having 5 amino adds at the N- 
term inal and possesses no C-terminal, (see fig. 1.3). Kambayaski et al. 
(1990) show ed that the sequence of BNP is species specific i.e. the 
spedficity of BNP is highly conserved within a spedes but not between 
spedes. This is in direct contrast to both ANP and CNP (Arimura et al
1991) where amino ad d  sequences are highly conserved between species. 
M ost experim ental data w ould seem to suggest that there exists an 
extended family of natriuretic  and diuretic peptides all sim ilar in 
structure, with related ligand-receptor action.
1.2 ATRIAL NATRIURETIC PEPTIDE RECEPTORS
1.2.1 Localisation of ANP receptors
The physiological effects of ANP are m ediated via interaction with 
spedfic  receptors in various target tissues. The determ ination of the 
am ino acid sequence of ANP and the use of radiolabelled ANP ligands 
has led to the identification and characterisation of ANP receptors. 
Specific ANP receptors have been identified in a wide variety of tissues, 
indud ing  kidney (Koseki et al. 1985), adrenal cortex (Meloche et al. 1986a; 
1986b), brain (Lynch et al. 1986) and lung (Olins et al. 1988). Specific ANP 
receptors have also been found in alm ost all animals so far studied, 
in dud ing  rat (Rugg et al. 1989), rabbit (Olins et al. 1988), ox (McCartney et 
al. 1990) and hum an (Schiffrin et al. 1988). The ANP receptor is thus 
ubiquitous in vertebrates. Details of these ANP receptors are summarised 
in the following section.
Figure 1.3
Amino acid sequences of porcine ANP, BNP, CNP and iso-rat ANP
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1.2.2 Characterisation of ANP receptors
M any aspects of ANP-receptor interaction have been investigated in 
several tissues in an attem pt to identify and characterise receptors in 
terms of their molecular size and type present and their respective second 
messenger systems. In the absence of completely pure ANP receptor 
protein, affinity labelling of ANP receptors w ith bifunctional cross- 
linking agents and photolabile analogues of ANP followed by sodium 
dodecyl sulphate polyacrylam ide gel electrophoresis (SDS-PAGE) and 
autoradiography has provided much information on the molecular size 
of these receptors. V andlen et ah (1985) used a photoaffin ity  
azidobenzoate derivative of ANP (^25i_AzBz-ANP) to bind to rabbit aortic 
membranes. Analysis after exposure to ultra-violet light and SDS-PAGE 
under reducing conditions (i.e. in the presence of p -m ercaptoethanol) 
revealed three distinct polypeptides of 120, 70 and 60 kDa. The same three 
polypeptides w ere labelled, w ith the 60 kDa com ponent being most 
intense, when the chemical cross-linkers disuccinymidyl suberate (DSS) 
and l,5-difluoro-2,4-dinitrobenzene (DFDNB) were used. In the same 
year Yip at al. (1985) utilised a photoaffinity N-hydroxysuccinimide ester 
derivative of ANP (I ^ ^I-iodoazidosalicylic acid-ANP) in binding studies 
with rat kidney cortex plasm a membranes. This group identified a 140 
kDa glycoprotein in rat kidney cortex plasma membranes and a 140 kDa 
protein was also specifically labelled in rat liver plasma membranes but 
not in rat adipose tissue. Hirose at at. (1985) solublised bovine adrenal 
cortex receptors w ith  3-[(3-cholam idopropyl) dim ethylam m onio]-l- 
propanosulfonate (CHAPS) before chemically cross-linking with DSS. 
They observed an ANP receptor protein of 130-140 kDa after SDS-PAGE 
under non-reducing conditions (i.e. in the absence of p-mercaptoethanol) 
and  a 70 kDa ANP receptor protein w ith SDS-PAGE under reducing
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conditions. The evidence of this group suggested that the native ANP 
receptor protein is composed of at least two subunits which together form 
a disulphide-linked 130-140 kDa unit capable of binding ANP.
The information obtained from  these initial crosslinking experim ents 
indicated the presence of at least three specific ANP receptors, one of 
approximately 60 kDa, one of approximately 120 kDa composed of two 60 
kDa subunits and one of approximately 120 kDa.
To further clarify ANP receptor m olecular size, type and  function, 
purification of the receptors was also attempted. Takayanagi et ai. (1987a) 
and  (1987b) purified tw o receptor types from bovine adrenal zona 
glom erulosa cell m em brane fractions, one w ith, and  one w ithout 
endogenous guanylate cyclase activity. Both receptors show ed high 
affinity binding to ANP, however the co-purified guanylate cyclase-linked 
receptor showed a low er affinity to ANP(io3-i23) and  ANP(io5-l2l) 
analogues, (these analogues lack the C-terminal phenylalanine-arginine 
residues and num bering refers to the amino acid position of proANP) 
than  the receptor w ith o u t guanylate  cyclase activity. U sing the 
photoaffinity derivative, 4-azidobenzoyl-l^% ANP and w ith SDS-PAGE 
under non-reducing conditions, both receptor types m igrated as a single 
135 kDa band. However, the presence of P-mercaptoethanol and SDS- 
PAGE revealed that the receptor w ithout guanylate cyclase activity 
m igrated as a 62 kDa band, whereas the co-purified guanylate cyclase- 
linked receptor remained at 135 kDa. Peptide m ap analyses of the primary 
structures of the two purified receptor subtypes from bovine adrenal zona 
glomerulosa cell m em brane fractions was performed. Takayanagi et al. 
(1987a) found that more than 90% of the peptides generated from the two
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receptors were different. Kuno et al, (1986b) supported the observation 
that ANP binding and guanylate cyclase activity occupied the same 
receptor protein. This group purified from ra t lung, a 120 kDa protein 
possessing both ANP binding ability and guanylate cyclase activity.
In addition to using bifunctional cross-linking agents and photolabile 
analogues to determine the size of ANP receptors, structural analogues of 
ANP which bind with differing affinities and to different receptor types 
have also successfully provided information on ANP receptor type. In 
1985, Garcia et al. (1985c) prepared a series of analogues produced by N- 
terminal chemical cleavage of synthetic ANP(ioi-i26) yielding ANP(io2- 
126)/ ANP(io3-126)/ ANP(io4-126) and ANP(io5-126) or C-terminal enzymatic 
digestion yielding (ANP(ioi-i21), ANP(ioi-i23)/ ANP(ioi-i24) and ANP(ioi- 
125). This group then examined the effects of these analogues and the 
additional synthetic analogues ANP(io3-l23)/ ANP(io3-i25)/ ANP(96-126) 
and ANP(54-i26) on the inhibition of noradrenalin-induced contraction of 
rabbit thoracic aorta. They observed ANP(ioi-i 26) to be the most potent 
with the N-terminally cleaved analogues also producing a marked 
inhibition of the noradrenalin response. In contrast, removal of amino 
acids from the C-terminal markedly decreased the inhibitory effect of 
AN P(io i-126). This observation indicated the importance of the ANP C- 
terminal in overcoming noradrenalin-induced contraction of rabbit 
thoracic aorta.
In the same year, Ballerman et al. (1985) showed that the affinity for ANP 
receptor binding in several cells and tissues was 10-1000 fold higher than 
the concentration of ANP required for half maximal stimulation of cGMP 
production. In support of this observation, Leitman & M urad (1986) and
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Scarborough et al. (1986) investigated the relationship between ANP 
analogue binding and stim ulated cGMP production in cultured bovine 
aortic endothelial and smooth m uscle cells. These two groups show ed 
that ANP analogues w hich w ere lacking in the carboxyl-term inal 
phenylalanine-arginine-tyrosine sequence retained a high affinity for 
nearly all vascular ANP receptors. However these ANP analogues were 
unable to stimulate cGMP generation or to antagonise the action of ANP 
stimulated cGMP generation. This observation was also supported by 
Leitman et al. (1986) w ho identified 130 and 66 kDa polypeptides in 
bovine aorta cultured endothelial cells, using the chemical cross-linker 
DSS. Leitman et al. (1986) show ed that 0.1 pM tyrosine-atriopeptin I 
([Tyr^]-ANP(4-25) a truncated AN P analogue lacking the carboxyl- 
terminal phenylalanine-arginine residues inhibited [125i]-aNP binding to 
the 66 kDa site to a similar degree as ANP however, was 150-fold less able 
to inhibit binding to the 130 kDa site. In addition [Tyr^]-ANP(4-25) was 
found only to produce a 4-fold increase in cGMP levels compared to a 400- 
fold increase produced with ANP. Leitman et al. (1986) speculated that 
the 130 kDa site was most likely coupled to a guanylate cyclase which was 
responsible for cGMP form ation  and th a t the carboxyl-term inal 
phenylalanine-arginine residues w ere im portant for linking the ANP 
receptor to the activation of guanylate cyclase. They also suggested that it 
was likely that the 66 kDa site was not coupled to guanylate cyclase. 
Lewicki et al. (1988) synthesised a series of ANP analogues which had 
systematic single am ino acid substitutions a t each position in the 17 
amino acid intramolecular sulphide loop structure or deletions of one to 
five amino acids from the carboxy-terminal end of the looped structure. 
Amino acid deletions from within the loop sequence of ANP resulted in 
100-1000 fold decreases in cGMP accumulation. However these same
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amino acid deletions had no effect on the binding affinity to ANP 
receptor sites not coupled to guanylate cyclase. Their investigations 
confirmed previous studies in cells and tissues and showed there were 
two ANP receptor populations in cultured bovine aortic smooth muscle 
cells.
The biochemical and pharmacological studies outlined above have led to 
the identification of at least two distinct ANP receptor subpopulations. 
One subpopulation  of biologically active receptors term ed ANP-B 
receptors has a molecular weight of approximately 130 kDa and is coupled 
to guanylate cyclase. The ANP-B receptor requires carboxyl-terminal 
phenylalanine-arginine residues for high affinity binding. Activation of 
ANP-B receptors by ANP results in the stimulation of cGMP production.
The other receptor subpopulaton is thought to be "clearance” receptors 
(Maack et al. 1987). That is, receptors responsible for the binding and 
rem oval of ANP from the circulation and have been term ed ANP-C 
receptors. These have a molecular weight of approximately 60 kDa and 
are able to bind various truncated ANP analogues with an almost equal 
affinity as ANP, Therefore, unlike the ANP-B receptor the ANP-C 
receptor does not require carboxyl-term inal phenylalanine-arginine 
residues for high affinity binding. ANP binding does not stimulate the 
production of cGMP with this receptor population.
1.2.3 Function of the ANP-B receptor and guanylate cyclase 
Guanylate cyclase has been identified in virtually all cell types examined. 
It is the enzyme which catalyses the formation of cGMP from guanosine 
triphosphate (GTP). In most cells this enzym e exists as a polymorphic
14
protein and its activity can be attributed to the coexistence of cytostolic 
(soluble) and membrane-associated (particulate) forms. These soluble and 
particulate  form s differ g reatly  in  their physical and  biochem ical 
functions and characteristics. The concentrations of each of these forms 
within the cell varies with cell type, physiological state and experimental 
protocol used to assay the enzyme. In the adult liver (Kimura & M urad 
1975a) or in blood platelets (Bohme et al. 1974) the soluble cytostolic form 
is predom inant. In contrast, the particulate form predom inates in 
regenerating and fetal liver (Kimura & M urad 1975b), intestinal mucosa 
(De Jonge 1975; Quill & W eiser 1975), retinal rod ou ter segm ents 
(Fleishman et al. 1980; Goridis et al. 1973; Krishanan et al. 1978) and in 
hepatomas and renal tum ours (Criss et al. 1976; De Rubertis & Craven 
1977; Goridis et al. 1977). In addition some cell types including Cô rat 
glioma, B103 rat neuroblastom a (Sinacore et al. 1983) and sea urchin 
sperm  (Gray & D rum m ond 1976; G arbers 1976; Radnay et al. 1983) 
exclusively possess the particulate form.
Soluble guanylate cyclase has been purified to apparent hom ogeneity 
from several sources and can be distinguished from the particulate 
enzym e by its sensitivity to exogenous nitro-vasodilators, such as 
n itrop russide , n itroglycerine, azides, n itrile  and the endogenous 
vasorelaxant nitric oxide, (endothelial-derived relaxant factor (EDRF)). 
This soluble guanylate cyclase enzyme has an apparent molecular weight 
of 150,000 Da (Garbers 1979; Lewicki et al. 1980; Gerzer et al. 1981a) and a 
haem group which may participate in its catalytic actions, (Gerzer et al. 
1981b; 1981c). For a full review of soluble guanylate cyclase regulation, 
activation and action, see W aldm an & M urad (1987).
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There are sim ilarities betw een ANP and the above m entioned  
vasod ila to rs. ANP is an endothelium  in d ep en d en t vasod ila to r 
(W inquist et al. 1984a). ANP relaxes angiotensin Il-induced contractions 
m ore efficiently than KCl-induced contractions (W inquist et al. 1984b). 
ANP increases levels of cGMP in various tissues, (H am et et al. 1984; 
H irata  et al. 1984). However, ANP activates the particu late  form of 
guanylate cyclase, (Tremblay et al. 1985a; W inquist et al. 1984b) and the 
vasodilators activate the soluble cytosolic form of guanylate  cyclase, 
(W inquist et al. 1984b).
Particulate guanylate cyclase can be classed into two groups (Waldman & 
M urad 1987), one which is readily soluble by detergents such as Triton-X- 
100 and one which is detergent resistant. The former enzym e is reported 
to be a large glycoprotein with a molecular weight of 200-400 kDa (Limbird 
& Lefkowitz 1975; Goldberg & Haddox 1977) and has been highly purified 
from rat lung (Waldman et al. 1985; Kuno et al. 1986b) w ith an apparent 
molecular weight of 200-300 kDa. It is possible that this enzyme exists as a 
dim er in the cell membrane since SDS-PAGE revealed a molecule with a 
molecular weight of 130 kDa. The second form appears to be a different 
isoenzyme which is resistant to solubilisation by detergents, EDTA, salt 
and  1 M urea. It can be found associated with the microvillus brush 
border of the intestinal mucosa (W aldman et al. 1986) and is most likely 
to be associated with cytoskeletal structures within the cell (Garbers 1989). 
Particulate guanylate cyclase is not stimulated by nitric oxide (Tremblay et 
al. 1985b), but can be activated by the heat-stable enterotoxin of Escherichia 
coli ST (Field et al. 1978), (which only stimulates the detergent insoluble 
form of particulate guanylate cyclase). As already m entioned a detergent- 
soluble particulate guanylate cyclase activity has been co-purified with
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ANP receptors from bovine adrenal cortex, (Takayanagi et al, 1987b) and 
solubilised plasma m em branes from  lung (Kuno et al. 1986b). This has 
led to the view that ANP binding and guanylate cyclase activity occupy 
the same transmembrane glycoprotein, (see section 1,2.5.2). ANP has also 
been observed to stim ulate  particu la te  guanylate cyclase activity in 
various tissues including, adrenal cortex (Waldman et al. 1984; Tremblay 
et al. 1985a; Takayanagi et al. 1987a), kidney (Waldman et al. 1984), liver 
(Kurose et al. 1987; W aldm an et al. 1984), testes (Marala & Sharma 1988) 
and lung (Kuno et al. 1986a), as well as several cu ltu red  cell lines 
(Leitman & Murad 1986).
There is some interest in utilising urinary levels of cGMP as a biological 
m arker for the action of ANP (Wong et al. 1988; Heim et al. 1988; Cogan et 
ai. 1989). However it has to be remembered that levels of urinary cGMP 
reflect not only the rate of production by the two identified forms of 
guanylate cyclase but also its degradation by phosphodiesterases inside
iand outside the cell (Hamet et al. 1986). Increasing intracellular levels of
cGMP, as a result of stim ulation by ANP are thought to induce vaso-
i
relaxation, (Rapoport et al. 1985; 1986). However there is conflicting 
evidence suggesting tha t cGMP does not m ediate AN P vasorelaxant 
actions (Budzik et al. 1987). In addition there is evidence that the ANP-B 
receptor m ay not signal entirely  through the p roduction  of cGMP, 
(Ganguly et al. 1989; G upta 1989). These observations suggest that the 
physiological and pharmacological effects may be m ediated by the ANP-C 
receptor population via interactions w ith signalling m olecules such as 
guanosine nucleotide b inding  proteins (Anand-Srivastava et al. 1986) or 
the ANP-B receptor m ay activate other second m essengers. ANP has 
been shown to inhibit phosphorylation of proteins (Pandey et al. 1987b;
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Elliot and Goodfriend 1985) in adrenal cells however Ganguly et al. (1989) 
observed no difference in p ro te in  p h o spho ry la tion  in adrenal 
glomerulosa cells stimulated by Ang II in the presence or absence of ANP.
1.2.4 Function of the ANP-C receptor
W hat is the function of this receptor? There have been two suggestions; 
1). a new, as yet unidentified 2nd messenger is coupled to the ANP-C 
receptor and 2). this receptor is involved in the sequestration and 
clearance of ANP from the circulation, (Maack et al. 1987). In general, the 
ANP-C receptor accounts for the majority of ANP binding sites in most 
cells/tissues and there is no correlation with ANP binding to this receptor 
population and the stim ulation of cGMP production, (Leitman et al. 
1985). The predom inance of ANP-C receptors over ANP-B receptors in 
m ost tissues, may explain the linear Scatchard plots often observed in 
[125i]-anP binding experim ents. Currently, there are no available 
antagonists for ANP, how ever analogues are available which have 
differing affinities for ANP-B or ANP-C receptors and are very useful 
tools for the investigation of these receptors. The ANP-C receptor has a 
red u ced  ligand  b in d in g  specificity  and the  carboxy-term inal 
phenylalanine-arginine residues of ANP are not required for binding. 
Studies have revealed that the most important residues for ANP binding 
to ANP-C receptor in  cultured bovine aortic smooth muscle (Maack et al. 
1987) and bovine endothelial aortic cells (Scarborough et al. 1986) are 
contained  w ith in  a sm all segm ent of the AN P ring  structure . 
Scarborough et al. (1989) p repared  a series of novel ANP-C receptor 
specific analogues w ith  conform ational changes in troduced  into the 
peptide. In these studies, the minimal ANP amino acid sequence which 
retained high affinity binding to the ANP-C receptor was an 8 amino acid
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segment of the 17 amino acid disulphide loop structure, (Phe-Gly-Gly- 
A rg-Ile-A sp-Arg-Ile-NH 2) . Scarborough et al. (1989) also suggested that 
that conformational adaptability of an ANP analogue, in a particular part 
of the sequence could be an im portant factor of the ANP-C receptor 
binding process. The ability of the ANP-C receptor to bind a variety of 
ligands, which now  includes ANP, BNP, CNP and iso-rANP (Sudoh et al. 
1988a; 1988b; Sudoh et al. 1990; Hynne et al 1989; Scarborough et al. 1989) 
is an unusual feature. The physiological significance of this reduced 
structural selectivity of ANP-C receptors rem ains uncertain. These 
investigations open up  the field for the development of analogues which 
can avoid the process of clearing through the ANP-C receptor thus 
providing a means of increasing circulating levels of endogenous plasma 
ANP concentrations.
Recently, A nand-Srivastava et al. (1989) and (1990) observed that ANP 
inhibited adenylate cyclase activity in rat platelet membranes. Only the 
ANP-C receptor population is present in rat platelets (Leitman & M urad 
1987). The physiological significance of platelet ANP receptors has yet to 
be established. Anand-Srivastava et al. (1990) also showed inhibition of 
adenylate cyclase activity in a dose-dependent manner (with ANP and des 
[QSGLG] ANP (4-23)-NH2), in anterior pituitary, aorta, brain striatum and 
adrenal cortical m em branes. This observation suggests that in these 
membranes ANP-C receptors may be negatively coupled to adenylate 
cyclase. A nand-Srivastava et al. (1990) speculated that ANP receptor 
coupling to adenylate cyclase was via an inhibitory guanine nucleotide 
regulatory  pro tein  (Gi). It should be borne in m ind that Geiger et al. 
(1990) in rat anterior pituitary and Cramb et al. (1987) in rat sarcolemmal 
membranes reported no inhibition of adenylate cyclase by ANP.
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To fully understand the nature of ANP receptor heterogeneity the use 
molecular biology techniques (e.g. molecular cloning and expression) are 
required.
1.2.5 Cloning and Expression of ANP receptors
1.2.5.1 ANP-B receptor
The isolation, sequence and expression of a cDNA clone encoding the 
mem brane form of guanylate cyclase from the rat brain was recently 
reported (Chinkers et al. 1989). The deduced amino acid sequence of the 
this receptor suggests an amino-terminal signal sequence and a single 
transmembrane dom ain that divides the protein into a 441 amino acid N- 
term inal ex tracellu lar dom ain and a 567 am ino acid C-term inal 
intracellular domain. The receptor has an apparent molecular weight of 
115,852Da and has six cysteine residues and six potential N-glycosylation 
sites in the extracellular domain. Regions of the intracellular domain are 
related to the catalytic dom ain of protein kinases, and also share 42% 
homology with the amino acids of the carboxy-terminal subunit of the 
bovine soluble form  of guanylate cyclase, Chinkers et al. (1989). 
Expression of this cDNA clone in COS-7 cells transfected using the 
mammalian vector pSVL, produces a m em brane protein that binds ANP 
with high affinity and also has endogenous guanylate cyclase activity. 
Lowe et al. (1989) isolated cDNAs encoding the hum an ANP-B receptor 
from placenta and kidney and expressed the cDNA clones in COS-7 cells 
transfected with the vector pRK (this group term ed the ANP-B receptor as 
the ANP-A receptor). This ANP-B receptor showed 90% amino acid 
sequence hom ology to the above m entioned ra t brain ANP-B receptor. 
Pandey & Singh (1990) have isolated a m urine Leydig cell ANP-B receptor 
which shows 97% amino acid sequence homology to the rat brain ANP-B
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receptor and 94% amino acid sequence homology to the ANP-B receptor 
isolated from hum an placenta (Lowe et al. 1989). Chang et al. (1989) 
reported expression, in COS-7 cells transfected with the vector pRK of a 
second placental hum an natriuretic pep tide / guanylate cyclase receptor. 
This second ANP-B receptor was show n at this time to be preferentially 
activated by BNP, (a 9.7 fold increase in cGMP) rather than ANP, (a 3 fold 
increase in cGMP). They also reported that the ANP-B receptor of Lowe et 
al. (1989), in terms of binding and guanylate cyclase activation, responded 
sim ilarly to both ANP and BNP (2 and 1,5 fold increases in cGMP 
respectively). These two receptors will generally be referred to as ANP-Bl 
receptor (previously referred to as hum an ANP-A receptor by Lowe et al. 
1989) and ANP-B2 receptor (previously referred to as the second hum an 
ANP-B receptor by Chang et al. 1989). Chang et al. (1989) reported this 
second receptor, ANP-B2 receptor to have an apparent molecular weight 
of 114,952 Da, w ith  six cysteine residues and seven potential N - 
glycosylation sites in the extracellular domain. The receptor was also 
found  to have a cytoplasm ic dom ain  of 569 am ino acids. The 
extracellular dom ain of hum an ANP-B2 receptor, (Chang et al. 1989) 
showed 44% amino acid sequence homology to human ANP-Bl receptor, 
(Lowe et al. 1989). The intracellular dom ains of hum an ANP-B2 and 
ANP-Bl receptors show ed an overall 74% homology w ith 63% in the 
protein kinase like dom ain and 88% in the soluble guanylate cyclase 
subunit homologous region. Schulz et al. (1989) reported the expression 
of tw o rat guanylate cyclase receptors, (termed GC-A and GC-B the rat 
equivalent of hum an ANP-B2 and ANP-Bl receptors respectively) in 
COS-7 cells transfected with the vector pSVL (these two cyclases showed 
an overall 62% am ino acid sequence homology). The in tracellu lar 
dom ains of these tw o receptors show ed 78% amino acid sequence
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homology (to each other) and the extracellular domains a 43% amino acid 
sequence homology. More recently , results from Koller et al. (1990) 
ind icated  th a t the new ly d isco v ered  CNP was the  m ost likely 
physiological ligand for the ANP-B2 receptor and that relatively high 
concentrations (500nM) of BNP w ere previously required to elicite a 
cGMP response with this receptor, Schulz et al. (1989) and Chang et al. 
(1989) (see fig. 1.4).
Recently, Schulz et al. (1991) identified a unique form of guanylate cyclase 
enzyme that does not recognise natriuretic peptides. This enzyme clone, 
termed GC-C was isolated from an intestinal cDNA library and expressed 
in COS-7 cells. GC-C was show n to exhibit the general structural features 
of ANP-Bl and ANP-B2, how ever show ed little amino acid hom ology 
com pared to the extracellular dom ains of ANP-Bl and ANP-B2. In 
addition GC-C was shown not to be stimulated by ANP, BNP or CNP but 
was stim ulated by the heat-stable enterotoxin of Escherichia coli ST and 
specifically bound i^Sjqabelled Escherichia coli ST. These results indicate 
the presence of at least one form of particulate guanylate cyclase which is 
not associated with natriuretic peptide binding.
To summarise, the plasma m em brane forms of ANP-B receptors contain 
a t least three distinct domains; extracellular ligand binding, intracellular 
catalytic protein-kinase like dom ain (similar to that seen in growth factor 
receptors such as platelet derived grow th factor (PDGF)). Chinkers et al. 
(1989) showed that a 256 amino acid portion of the intracellular dom ain 
of their ANP-Bl receptor was 31% identical to the protein kinase dom ain 
of PGDF receptor. Finally an intracellular domain which is hom ologous 
to a subunit of a bovine soluble form  of guanylate cyclase. ANP-Bl and
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Figure 1.4
Hormone specificity for the hum an natriuretic peptide receptors, ANP-BRl, ANP-BR2 and ANP-C
Hormones
ANP
BNP - i
CNP
Receptors
Kinase bomologous Guanylyl cyclasc domain domainJ ANP-BRl
3 ANP-BR2
ANP-C
Transm cmbrancExtracellular Intracellular
Not physiologically significant
Physiologically significant
ANP-B2 receptors are a single transm em brane class of receptors which 
function uniquely by coupling to endogenous guanylate cyclase activity 
and may exist as a family of m any members all varying in their ligand 
binding domains.
1.2.5.2 ANP-C receptor
In 1988, Fuller et al. (1988) isolated, sequenced and expressed cDNA clones 
encoding the bovine ANP-C receptor. The full length amino acid 
sequence of the ANP-C receptor w as established from these clones and 
was found to be synthesised as a 537 amino acid precursor with an 
apparent molecular weight of 59,744 Da. Amino acid analysis of the 
cDNA suggested that the m ature form  of this receptor consists of a 496 
am ino acid extracellular dom ain consisting of the ANP binding site, a 
single hydrophobic transmembrane anchor of 23 amino acids and a short 
carboxy-terminal cytoplasmic tail of 37 amino acids. A cDNA clone was 
transcribed in vitro and the resulting synthetic mRNA microinjected into 
Xenopus oocytes. These in turn  expressed an endogenous ANP receptor, 
possessing high affinity binding for ANP, truncated ANP(io3-i23) and des 
[QSGLG] ANP (4-23)-NH2. These observations were supported by Porter 
et al. (1988; 1989). Porter et al. (1989) utilised a vaccinia virus expression 
system  transfected with the plasm id pS C ll to characterise a m utant 
receptor which lacked the transm em brane and cytoplasmic domains of 
the ANP-C receptor. Their results indicated that the extracellular domain 
of the ANP-C receptor is sufficient for high affinity binding since the 
m utant receptor had binding affinities for ANP and des [QSGLG] ANP (4- 
23)-N H 2 identical to that of the native ANP-C receptor. The cDNA 
sequence of the hum an ANP-C receptor has also been elucidated, (Lowe et 
al. 1990; Porter et al. 1990) and  is found to comprise of a 540/541 amino
23
acid precursor with an apparent m olecular weight of 59811Da. This 
hum an ANP-C receptor has 93/95% amino add  sequence homology with 
the bovine ANP-C receptor. Fuller et al. (1988) and 33/35% amino acid 
sequence homology w ith the rat and hum an ANP-Bl receptor, Chinkers 
et al. (1989) and Lowe et ai (1989) respectively.
The above information therefore indicates the presence of a unique 
family of related natriu retic/d iuretic  peptides in co-existence with an 
equally unique family of na triu retic / diuretic peptide ligand binding 
receptor sites. It therefore rem ains to sum m arise the mechanisms 
controlling the release of ANP and its subsequent physiological actions 
and finally, to examine the role of ANP in hypertension.
1.3 ANP RELEASE AND PHYSIOLOGICAL ACTIONS
1.3.1 M echanisms controlling the release of ANP
In general the release of hormones from cells is thought to be regulated by 
three internal pathways, (Lang et al. 1987). One employs ATP and the 
enzyme adenylate cyclase, then generating the second messenger cAMP. 
A second employs calcium ions, where cytosolic calcium can be increased 
by calcium entering the cell through selective mem brane channels or be 
m obilised from  intracellular stores, e.g. the endoplasm ic reticulum . 
Calcium release from these intracellular stores is initiated by inositol 
1 ,4 ,5 - tr ip h o sp h a te  (IP3 ), w hich  is generated  from  m em brane 
phosphoinositides along w ith diacylglycerol (DAG). IP3 and DAG form 
part of the third internal pathw ay, the phosphatidylinositol (PI) system. 
Protein phosphorylation, m ediated by protein kinases, is one of the final 
steps of all the pathways and may facilitate the transport and fusion of 
secretory granules with the cell membrane. Cyclic AMP (cAMP) and DAG
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are responsible for the activation of protein kinase A and C respectively. 
The activation of protein kinase C requires calcium which is mobilised 
from intracellular stores by IP3. Thus, IP3 and DAG are synergistic in the 
activation of protein kinase C. The use of pharmacological agents which 
mimic the actions of specific second messengers can be used to assess the 
part played by each pathway in mediating horm one release. Lang et al. 
(1987) investigated the effects of activation of the calcium calmodulin 
pathw ay by A23187 (a calcium ionophore) and BAYK8644, (a calcium 
channel agonist) on the release of ANP. Both A23187 and BAYK8644 
introduce free calcium into the cell therefore they can be used to mimic 
the actions of IP3. Lang et al. (1987) also investigated the effects of 12-0- 
tetradecanoylphorbol-13-acetate (TPA, a phorbol ester which stimulates 
protein kinase C) and forskolin (which is known to activate adenylate 
cyclase and cause an increase in cAMP levels) on the release of ANP. 
They found that all of the above mentioned pharmacological agents had 
stim ulatory effects on ANP secretion and that TP A plus A23187 or 
BAYK8644 had a more than additive effect. These results suggested that 
ANP secretion is a calcium dependent process and that elevated calcium 
may contribute to the activation of protein kinase C (Lang et al. 1987).
The release of ANP from the heart is therefore stim ulated by cytosolic 
calcium concentrations, which in turn can be augm ented by cAMP and 
protein kinase C (Lang et al. 1987). The concentration of calcium in the 
heart is dependent upon m any factors, including the action of various 
hum oral substances, cardiac nerve activity, heart rate  and the m ean 
length of heart fibres. This invites speculation that these factors m ay also 
play a role in the regulation of ANP release.
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Indeed there is evidence that ANP release is increased by adrenalin and 
arginine vasopressin, (Sonnenberg et al. 1984; Sonnenberg & Veress 1984).
A role for the autonom ic nervous system in the regulation of ANP 
release has also been suggested  since it has been observed that 
acetylcholine, (Sonnenberg & Veress 1984) and catecholamines, (Lang et 
al. 1987) both stimulate the release of ANP from rat atria in vitro.
Increased plasma ANP levels are found during tachycardia or when atrial 
pacing is m aintained a t high frequencies (Tikkanen et al. 1985). The 
release may be directly due to the increased heart rate or may possibly 
result from an increase in atrial filling pressure increasing atrial tension. 
ANP plasma concentrations have been reported to be elevated in patients 
w ith congestive heart failure (Tikkanen et al. 1985), and children with 
congenital heart diseases and bronchopulmonary abnormalities (Lang et 
al. 1985). These conditions are associated w ith increased atrial filling 
pressure which causes distension of the atrial wall. D ietz (1984) has 
shown a positive correlation between ANP secretion rate and atrial filling 
pressure in man (patients w ith coronary heart disease) and  rats (animals 
subjected to acute volum e loading). Fluid (Lang et al. 1985) and salt 
loading (Sagnella et al. 1985) have also been shown to increase right atrial 
pressure with a rise in  ANP plasma concentration. Changes in posture, 
which affects venous re tu rn  (Hodsman et al. 1985) and head-out water 
immersion (Katsube et al. 1985), have also been shown to  be associated 
with increases in plasm a ANP concentration and are correlated with an 
elevation in right atrial pressure. In vivo atrial stretch has also been 
observed to induce ANP release, (Ledsome et al. 1985).
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Humoral, cardiac nerve activity and heart rate factors are all indicated in 
ANP release however, m yocardial fibre length  is possibly the m ost 
im portant factor. Secretion of ANP may be influenced by the rise in free 
intracellular calcium which is observed w hen m yocardial fibre length is 
increased, (Lang et a l 1987).
1.3.2 Physiological effects of ANP
The observation by De Bold et al, (1981), of a vast increase in renal sodium 
and water excretion initiated by an atrial protein, (ANP) led to much 
experim entation on the m echanism s by w hich ANP m ediates this 
response. ANP has been show n to have a num ber of actions when 
studied in vitro and in vivo. These actions include an inhibition of renin 
and aldosterone secretion, relaxation of preconstricted smooth muscle 
and alterations in renal vascular haemodynamics. (The latter, although 
an im portant effect of the physiological action of ANP will not be 
discussed in this thesis due to the vast am ount of information available 
and the difficulty involved in condensing this inform ation to a brief 
sum m ary).
1.3.2.1 The Effects of ANP on Renin Release
W hen ANP is secreted from cardiocytes in response to a release stimuli 
such as atrial stretch, it is transported via the arteries, to its various target 
tissues. Once ANP has reached these targets its prim ary role is to modify 
the m echanisms which regulate  blood pressure and blood volume. In 
particular ANP interacts w ith  the renin-angiotensin system. Renin is 
secreted by juxtaglom erular cells into the bloodstream  when blood 
pressure and sodium  concentration in the kidney tubule is low (Cantin & 
Genest 1986). Renin cleaves the plasma protein angiotensinogen which
2 7
in turn  forms the decapeptide angiotensin I which is converted to the 
octapeptide angiotensin II by angiotensin converting enzym e (ACE) 
w hich is m ainly found in the lung. A ngiotensin II is a pow erful 
vasoconstric to r w hich  suppresses fu rth er release of ren in  from  
juxtaglom erular cells and stimulates the release of aldosterone from the 
adrenal gland. ANP affects the renin-angiotensin system by inhibiting 
the release of renin  and by directly inhibiting the adrenal secretion of 
aldosterone. The exact mechanisms by which ANP suppresses renin 
release are not as yet fully understood and are controversial. Opgenorth 
et a l (1986) have show n that ANP does not suppress renin secretion in 
the non-filtering kidney, this suggested that the suppressive mechanism 
m ay involve the m acula densa cells of the distal tubule. Recently, 
Kagayama and Brown (1990) have shown that ANP renin suppression is a 
calcium independent mechanism.
A lthough the general consensus is that ANP suppresses the release of 
renin (Kagayama & Brown 1990; Cody et al. 1986; Kurtz et al. 1986), renin 
has also been reported  to be increased (Hirum a et al. 1986) or rem ain 
unchanged (Rodeiguez-Puyol et al. 1986) after administration ANP.
1.3.2.2 The Effects of ANP on Aldosterone Release
In contrast to the conflicting evidence concerning ANP's actions on renin 
secretion, A tarashi et al. (1984), (using crude atrial homogenates) and 
C hartier et al. (1984), DeLean et al. (1984) and Goodfriend et al. (1984), 
(using synthetic peptides) have show n that ANP directly inhibits the 
secretion of aldosterone from the adrenal gland. In the same year 
C hartier et al. (1984) observed in  ra t zona glom erulosa cells, th a t 
angio tensin  II (A ngll), adrenocorticotrophic horm one (ACTH) and
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potassium  chloride (KCl) stim ulated aldosterone secretion was inhibited 
by ANP and in prim ary cultures of bovine zona glomerulosa cells ANP 
show ed up  to 70% inhibition  of A ngll, ACTH, prostag land in  and 
forskolin stimulated aldosterone secretion. Atarashi et al. (1984) showed 
evidence of a preferential inh ib ition  of ANP on A ngll-stim ulated  
secretion, since a high concentration of A ngll (lO ^M) was unable to 
overcome the inhibitory effect of ANP on aldosterone release. There is 
evidence (Goodfriend et al. 1984; Elliot & Goodfriend 1986; Kudo & Baird 
1984) to suggest that the m echanism of ANP inhibition is at some early 
part of the steroidogenic pathw ay, before m itochondrial up take  and 
metabolism of cholesterol. Lawrence et al. (1990) has shown in hum ans 
on a low salt diet and under induced hypoxic conditions, increases in 
plasma ANP which coincide w ith decreases in plasma aldosterone. How 
this depressive action on aldosterone secretion contributes to the actions 
of ANP remains to be established. H igh and low affinity receptors for 
ANP, w hich are distinct from  ACTH and Angll receptors, have been 
identified in bovine adrenal zona glom erulosa membranes (DeLean et al 
1984, Meloche et al. 1987a; 1987b) and it is likely that these m ediate the 
effects of ANP on the cells.
1.3.2.3 Vascular effects of ANP
Deth et al. (1982) and C urrie  et al. (1983) have suggested th a t the 
hypotensive actions of ANP m ay be m ediated via vasorelaxation. These 
two groups reported the relaxation of aortic strips in vitro by ra t atrial 
extracts. Subsequently, it was confirmed that extracted ANP (Garcia et al.
1984) and synthetic ANP (Atlas et al. 1984; Garcia et al. 1984; Cohen & 
Schenk 1985) act in a similar m anner. The general vasorelaxant response 
of ANP is independent of the vasoconstrictor and similar results are
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found w ith A ngll, noradrenaline, histamine and caffeine. There have 
however, been variable results observed with the actions of ANP on KCl- 
induced  vasoconstriction (Garcia et al. 1984; R apoport et al. 1985 & 
Bratveit et al. 1987). The actions of ANP on KCHnduced vasoconstriction 
are not yet fully  understood , however it is though t tha t reported 
differences may be due to the various alterations in intracellular calcium 
(Ca^+). A ngn and noradrenaline act by releasing Ca^+ from intracellular 
stores e.g. the endoplasm ic reticulum  (Deth & Van Breeman 1977; Van 
Breeman et al 1982). Chui et al. (1986) and Meisheri et al. (1986) showed 
that ANP inhibited agonist stimulated intracellular Ca^+ release and Ca^+ 
influx, however they found that ANP had no effect on KCl-stimulated 
Ca2+ influx. This is perhaps because the m em brane depolarisation 
induced by high potassium  is not as sensitive to the relaxant effect of 
ANP compared to that of A ngll and noradrenaline induced contractions 
(Chui et al. 1986).
The vasorelaxant actions of ANP are generally considered to be mediated 
by increases in in tracellular cGMP (Rapoport et al. 1985; 1986). The 
increases in cGMP causes activation of a cGMP-dependent protein kinase 
which may lead to the inhibition of Ca^+ translocation through agonist or 
recep tor-operated  Ca^+ channels a n d /o r  enhance Ca^+ extrusion via 
activation of the sarcolemma extrusion pum p (Popescu et al. 1985) an d /o r 
interfere w ith the release of Ca^+ from in tracellu lar storage sites. 
Ultimately, the result is a decrease in Ca^+ and vasorelaxation. However 
recently , Budzik et al. (1987) studying the effects of various ANP 
analogues in cultured vascular smooth muscle cells observed dissociation 
between ANP analogue stim ulated increases in cGMP and ANP analogue 
vasorelaxation of preconstricted rabbit aorta. The extent of vasorelaxation
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is dependent upon the vascular preparation (Garcia et al. 1984; Cohen & 
Schenk 1985) and the analogue of ANP used. The ring structure of ANP 
is known to be im portant for binding, (Misono et al. 1984a; 1984b), and 
changes at the C-term ini of ANP have been show n to decrease the 
vasorelaxant effect of ANP, (Garcia et al. 1985c). In  general, the 
vasorelaxant activities of ANP are more effective in arterial rather than 
venous preparations and  this correlates with num bers of receptors in 
these tissues (Cohen & Schenk 1985). W inquist et al. (1985) found large 
num bers of high-affinity ANP B-receptors in both aorta and renal artery, 
intermediate numbers in pulm onary artery and vein and low  numbers in 
ear and femoral arteries which all correlated w ith the dose dependent 
vasorelaxation response to ANP. However this group also found large 
num bers of high-affinity ANP B-receptors on renal and jugular veins, 
w ith  a poor correlation between ANP receptor binding and  relaxation 
response. Therefore differences in receptor localisation a n d /o r  density 
cannot solely account for the observed differences in vasorelaxation of 
isolated vascular preparations.
In vivo animal studies are not in complete agreem ent w ith  in vitro 
studies. Some reports indicate that adm inistration of ANP results in a 
decrease (Volpe et al. 1986), an increase (Koike et al. 1984), or no change 
(Lappe et al. 1985) in total peripheral resistance. However administration 
of ANP (atrial extract or analogues of ANP) has generally been shown to 
cause a reduction in m ean arterial pressure (Pegram et al. 1986), with the 
greatest reductions noted  in studies on hypertensive animals. In the 
hum an, Richards et al. (1985) observed symptoms of arterial vasodilation 
(flushing, reflex tachycardia, increased skin blood flow) after injection of 
A NP in healthy volunteers.
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1.4 ATRIAL NATRIURETIC PEPTIDE AND HYPERTENSION
1.4.1 Hypertension
Hypertension (high blood pressure) is defined as a chronically increased 
arterial pressure. Abnormally high blood pressure (BP) may be associated 
w ith several known diseases (Secondary Hypertension), or may occur 
spontaneously w ith no apparen t clinical disorder being diagnosed 
(Essential or P rim ary  H ypertension). In the case of secondary 
hypertension  the increase in blood pressure is a resu lt of some 
d iso rder/cause  which can be clearly identified, e.g. d rug  induced, 
neurogenic and renal d isorders or can be associated w ith horm onal 
changes induced by pregnancy. In the case of essential hypertension 
which accounts for 80-95% of all patients with hypertension, the actual 
cause is unknown. It is this type of hypertension which has been studied 
m ost closely with regard to ANP and its natural hypotensive actions in 
resisting increases in intravascular volume and blood pressure. A widely 
used scheme grading levels of essential hypertension (Bowman & Rand 
1980) is as follows; Grade 1 mild hypertension; patient BP is considered to 
be above the normal values of 120/80mmHg (systolic/diastolic) but is 
consistently less than 170/llO m m H g; Grade 2 moderate hypertension, 
patien t BP is greater than  170/1 lOmmHg and there evidence of left 
ven tricu lar hypertrophy ; Grade 3 severe hypertension, patien t BP is 
greater than 170/1 lOmmHg and there are signs of marked left ventricular 
hypertrophy  and of im paired  renal function, in particular a serum  
creatinine concentration exceeding 15m g/l and; Grade 4 m alignant 
hypertension, patient show  a high and rapidly increasing BP, diastolic 
pressure at this time is usually greater than 130mmHg and the condition 
is associated with retinal haem orrhages and occasionally complications
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such as heart failure, stroke and  renal impairm ent. This grade of 
hypertension is usually fatal to 90-95% of patients if untreated.
Sugaw ara et a l (1985) and Sagnella et al. (1986) have shown that in 
patients with a moderate degree of essential hypertension there is an 
associated increase in plasm a ANP concentration and there appears to be 
a correlation betw een atrial pressure and plasma ANP concentration as 
the levels of hypertension progress. Sagnella et al. (1986) and Richards et 
al, (1986) have also reported increases in plasma ANP concentration w ith 
age in normotensives and BP is know n to rise with age (Beevers 1987). 
However there rem ains a great deal of controversy in reports concerning 
mild essential hypertension. Yamaji et al. (1986), Larochelle et al. (1987) 
and Nilsson et al. (1987) all agreed that there was no change in plasm a 
A N P concentration  in p a tien ts  w ith  m ild  u n tre a te d  essen tia l 
hypertension, com pared to norm otensive control subjects. Conversely, 
Montorsi et al. (1987) show ed a significant increase in ANP levels (45 ± 3 
p g /m l compared to 36 ± 3  p g /m l) with a mild hypertensive group of 
patients. An im portant factor to consider when analysing these results is 
the degree of standard isation  betw een the groups since plasm a ANP 
concentration can vary  w ith all of the following factors; dietary sodium 
intake (Tanaka et al. 1984); age (Beevers 1987); posture (Hodsman et al.
1985) and possibly race and physical ability. There is also som e 
speculation that during the early stages of development of certain types of 
essential hypertension there may be a deficiency in secretion of ANP w ith 
a concomitant increase in blood pressure which may play a primary role 
in inducing, m aintaining or enhancing the effects of hypertension. This 
hypothesis is supported  by Perrier et al. (1988), w ho exam ined the 
children of hypertensive patients w ith regards to their response to an
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increase in dietary sodium . Results of this study indicated a lack of 
sodium  induced increase in plasm a ANP concentration compared to 
children of normotensive subjects. This report was supported by Tunny 
et al. (1986) who examined Gordon's syndrome (hypertension is present 
associated w ith hyperkalaem ia and volum e expansion), where plasma 
ANP concentration  w ere near to norm al perhaps indicating an 
attenuation of response of plasma ANP. Schiffrin et al. (1988) has studied 
in platelets isolated from patients w ith essential hypertension, the 
relationship betw een plasm a ANP concentration and ANP receptor 
density  (platelets are known to express only the ANP-C receptor 
population). This group  reported a decrease in the density of ANP 
receptors in hypertensive patients w ith an inverse correlation to plasma 
ANP concentration. Administration of ANP in varying pharmacological 
doses to patients suffering from essential hypertension has revealed 
various results, (for a fuller review see Richards (1990). It is generally 
accepted that prolonged administration of physiological doses of ANP 
(0 .5-2 pm ol/kg /m in) results in a fall in arterial blood pressure with a mild 
negative alteration in sodium balance, w ithout activation of the reflex 
counterbalancing m echanism s, such as stim ulation  of the renin- 
ang io tensin-aldosterone system (RAAS) and  sym pathetic  nervous 
system . In  a d d itio n  there are  no  signs of the  extensive 
hypotension/bradycardia noted with high ANP infusion doses such as 64- 
144 p m o l/k g /m in  (Weder et al. 1987). These observations open the way 
for the use of ANP, ANP-analogues or agents w hich prevent the 
degradation of endogenous ANP in the treatment of hypertension.
To examine the relationship between ANP and hypertension various 
anim al m odels have been studied as well as studies in the human.
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Changes in the density and /o r the affinity of target organ/tissue receptor 
sites for ANP and plasma ANP concentration m ay alter as hypertension 
develops.
1.4.2 The effects of salt-loading and dehydration in  Sprague-Dawley rats 
Marie et al. (1976) and De Bold (1979) dem onstrated that water loading 
and increasing sodium  caused significant decreases in the num ber of 
atrial ANP containing granules. This initial observation has led to the 
investigation of the effects of salt and w ater dietary alterations on plasma 
ANP concentration, ANP receptor density, tissue and plasma cGMP levels 
and BP in m any animal models.
Kollenda et al. (1990) investigated the short term  (3 days) effects of salt 
loading (1% saline in drinking water) in male Sprague-Dawley rats. They 
reported that salt loading did not induce any significant change in plasma 
ANP concentration or in ANP receptor density in glomeruli membranes. 
This result was supported by Morton et al, (1987) who studied alterations 
in sodium diet (over 10 days) in male Sprague-Dawley rats. They showed 
no change in p lasm a ANP concentration w ith  high (1% saline in 
drinking water) or low (0.002% saline in drinking water) salt diets in male 
Sprague-Dawley rats. Ballerman et al. (1985) examined the effects of both 
salt depletion and  administration of isotonic saline after 14 days, on 
glom erular AN P receptor density in m ale Sprague-Dawley rats. They 
concluded that a high salt diet resulted  in a reduction (4-fold) in 
glom erular ANP receptor density and an increase in receptor affinity 
relative to the values for the low salt diet rats. There was no change in 
glom erular AN P-induced cGMP production w ith  the different diets. 
Plasma ANP concentration was 132 ± 63 pM  and 23 ± 5 pM in the high salt
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and salt depleted rats respectively. Ballerman et al. (1985) speculated that 
the altered glomerular ANP receptor is not directly linked to guanylate 
cyclase and that alterations in body fluid volume m ay be reflected in a 
decrease in glom erular ANP-C receptor density. Michel et al. (1990) 
investigated salt loaded (0.9% saline in drinking water) male Sprague- 
Dawley rats after 35 days. Plasma ANP, renal function, BP and cGMP 
levels all rem ained the same, com pared to control rats receiving 
deionised water, however this group did observe a down-regulation of 
receptor num bers (predom inately ANP-C receptors) in isolated renal 
glomeruli compared to control rats. Widimsky et al. (1990) also examined 
the long term effects of salt loading in male Sprague-Dawley rats. These 
investigators reported that a prolonged high-salt diet (8 % w /w  NaCl rat 
chow) after 5 wk but not 3 wk, caused an increase in metabolic clearance 
rate and volume distribution of 'vvhen com pared to control
rats, (0.8% w /w  NaCl rat chow). They also noted a greater [^^^Il-ANP 
uptake in various tissues after 5 wk but not after 3 wk, on the high salt 
diet. From their results they hypothesised that prolonged salt ingestion 
increases the density a n d /o r  affinity of ANP binding sites, (most probably 
ANP-C receptors) and that this m ay explain the previously observed 
(Debinski et al 1988) decreases in  plasm a ANP concentration after 
prolonged salt ingestion (5wk).
The general consensus (with the exception of Widimsky et al. 1990) is that 
an increased salt diet causes a decrease in glomeruli ANP receptor density 
in the Sprague-Dawley rat. The indications are that time is an im portant 
factor in causing, most likely ANP-C receptor down-regulation.
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Schwartz et al. (1986) showed that three days of water deprivation caused 
a significant decrease in plasma ANP concentration compared to controls. 
This observation was supported by Kollenda et al. (1990). They observed 
that dehydration, (no w ater for 3 days) in m ale Sprague-Dawley rat 
glomeruli, leads to a decrease in plasm a ANP concentration and an 
increase in ANP-C receptor density. They speculated that the inverse 
relationship between plasm a ANP concentration and ANP-C receptor 
density  could be an adaptive  m echanism  for m aintain ing  fluid 
homeostasis.
1.4.3 Genetic experimental models for Hypertension
1.4.3.1 The Spontaneously hypertensive rat (SHR)
Sonnenberg et al. (1983) reported that the ANP concentration per atria of 
SHR was lower than in normotensive W istar-Kyoto (WKY) control rats. 
Radioimmunoassay (RIA) showed that the ANP concentration per unit 
w eigh t of atrium  w as sim ilar in bo th  stra ins at w eaning but as 
hypertension developed w ith age, the ANP concentration in the left atria 
of SHR decreased relative to WKY with the ANP concentration in the 
right atria rem aining constant. Higa et al. (1985) and Takayanagi et al.
(1986) also showed sim ilar results with age developed hypertension in 
SHR. The plasma ANP concentration in the study of Higa et al. (1985) 
w as reported to be low er in SHR than in WKY. However in contrast, 
Im ada et al. (1985), Takayanagi et al. (1986) and Morii et al. (1986) found 
sim ilar plasm a ANP concentration in both strains w hen young but 
higher plasma [ANP] in SHR as the rats aged and became hypertensive.
Takayanagi et al. (1986) also showed that there was a decrease in ANP 
receptor density (Bmax) in aortic smooth muscle m embranes and adrenal
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membranes in SHR, with an inconsistent increase in cGMP response 
even before the onset of hypertension. Conversely, in cultured aortic 
vascular smooth muscle cells, N akam ura et al. (1988) found an increase 
in receptor density and an increase in Ka in the SHR. However, despite 
the increase in receptor density for ANP there was a lower maximal 
stimulation of cGMP in response to ANP. The difference in receptor 
density of these two reports is perhaps a result of the experimental 
conditions used. In the report of Takayanagi et al (1986) the increased 
ANP concentration is likely to down regulate receptor density. However 
in the report of N akam ura et al (1988) there was no prior exposure to 
increased circulatory plasma ANP, hence no down regulation of receptor 
density. These result suggest that in vivo and in vitro results should 
perhaps be interpreted with some caution.
Saavedra et al. (1986b) investigated the ANP receptor population in 
subfornical organ (SFO), choroid plexus (CP) and the olfactory bulb (OB) 
in SHR and age matched WKY normotensive control rats. They reported 
a decrease in the num ber of binding sites for ANP and a lower Kd (higher 
affinity) for 4 wk and 14 wk SHR in the SFO, also a decrease in ANP 
receptor density w ith  no difference in Kd in the CP. They found no 
difference in ANP receptor density or Kd with OB. These investigations 
were supported by Brown & Czarnecki (1990) who also reported a 
reduction in the num ber of binding sites for ANP in SHR in the SFO and 
in the CP bu t no reduction in arachnoid mater (AM). Brown & Czarnecki 
(1990) also showed a lower Kd in SFO and CP but no change in AM. 
O kazaki et al. (1990) exam ined ANP bind ing  sites in the cerebral 
microvessels and in the CP of SHR and WKY. In the microvessels they 
found no difference in  affinity but a lower Bmax in SHR compared to
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WKY and in the CP a higher affinity and a lower Bmax in SHR compared 
to WKY. Garcia et ah (1981) and Johanson (1976) showed increases in the 
diam eter, evidence of endothelia l cell degeneration and collagen 
deposition in cerebral capillaries w ith experim ental hypertension in 
humans and monkeys. Hypertension therefore causes changes in cerebral 
m icrovasculature and ANP receptors in cerebral microvessels and the 
choroid  p lexus m ay p a rtic ip a te  in the regu la tion  of cerebral 
microcirculation. The SFO is a structure which lies outside the blood- 
brain barrier and is therefore exposed to circulating blood peptides, the 
SFO may then also act to regulate cerebral microcirculation. In 1987, 
Chabrier et al. (1987) speculated that ANP receptor sites in norm otensive 
bovine brain microvessels were indicative of a potential physiological 
effect of ANP on brain microcirculation an d /o r the blood-brain barrier.
Ogura et al. (1987) examined renal (whole kidney) receptors of ANP in 5 
wk and 12 wk SHR. They reported increases in BP, decreases in Bmax and 
decreases in K^ for both groups of SHR. However, the increase in BP in 
the 12 wk group and the decrease in binding capacity were both greater. 
Garcia et al. (1989) investigated glomerular ANP receptors in 4, 6, 12 and 
16 wk SHR. ANP receptor density was reported to be similar in 4 w k SHR 
and age matched WKY controls. However, ANP receptor density in SHR 
was reported to be lower than age matched WKY controls at 6,1 2  and 16 
wk. A lower K j compared to controls was also noted at 6 and 12 wk. ANP 
stim ulated cGMP production was reported to be lower in SHR than in 
WKY, suggesting a possible dow n-regulation in the ANP-B receptor 
population. Brown et al. (1990) using the synthetic ANP analogues, des 
[QSGLG] ANP (4-23)-NH2 (des-ANP) which is specific for ANP-C receptors 
and rat A triopeptin 1 (ANP(5-25)) which selectively relaxes intestinal
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sm ooth m uscle but not vascular sm ooth muscle stripes (Currie et al. 
1984c), investigated ANP receptor subtypes in renal, (glomeruli, stripes in 
outer m edulla and in inner medulla) of SHR and WKY. They showed 
th a t des-A N P and  ANP(5-25) inh ib ited  [1 2 5 i]-an P  b in d ing  by 
approxim ately 70% in the glomeruli b u t showed no inhibition of [^25i]_ 
ANP binding in the m edulla of both  SHR and WKY. However, the 
receptor sites of the glomeruli and of the medulla able to bind [^^Sjj-ANP 
in the presence of lOpM des [QSGLG] ANP (4-23)-NH2 were different in 
the SHR compared to the WKY. In the WKY ANP(5-25) was unable to 
displace [^25i]_anP glomerular binding and did not displace more than 
40% of [125i]_anP medullary binding. In contrast, in the SHR [^25i].aNP 
binding was completely displaced by ANP(5-25). SHR glomeruli and 
m edulla also showed a lower Ky and a lower Bmax com pared to WKY. 
These results suggested that ANP-C receptors are restricted  to the 
glomeruli and not the medulla. Also that binding sites of the medulla 
are most likely ANP-B receptors, (guanylate cyclase coupled) and that the 
ANP-B receptors in SHR have, like WKY, a low affinity for des-ANP, bu t 
differ from WKY in possessing a higher affinity for ANP(5-25), The 
actions of ANP(5-25) in the glomeruli and the medulla of SHR indicate 
that ANP(5-25) although having a greater affinity for the ANP-C receptor 
than for the ANP-B receptor is competitively binding at another receptor 
site. This other receptor site maybe the ANP-B2 receptor (See 1.2.5.1) or a 
defect in receptor guanylate cyclase activity may somehow alter receptor 
binding characteristics (Brown et al. 1990). (These results do not rule out 
the presence of low numbers of B receptors in the glomeruli).
Kurihara et al. (1987) reported a decrease in ANP receptors in the thymus 
and the spleen of young (4 wk) SHR compared to age m atched WKY.
4 0
ANP-stimulated cGMP production was reported to be similar, suggesting 
a possible dow n-regulation in the ANP-C receptor population in the 
thymus and the spleen. This group indicated that reduced ANP binding 
was present before the development of hypertension and that it persisted 
after hypertension had developed.
The above results are conflicting. There is general agreement that in the 
SHR there is a down-regulation of ANP receptors with a decrease in Kd, 
however there is controversy as to which receptor population is down- 
regulated and w hat happens to  cytosolic cGMP concentration. Alterations 
in ANP receptor density is also implicated in organs of the im m une 
system during hypertension. As to changes in plasma ANP levels, there 
is again much controversy w ith no real consensus to the reported results. 
H ow ever, it w ould seem that in all cases ra t age is an im portant 
determ inant of ANP concentration in the blood.
1.4.3.2 The Dahl hypertensive rat
Dahl et al. (1962) selectively bred rats for sensitivity (S) or resistance (R) to 
the hypertensive effect of a high salt diet, (a m odel of essential 
hypertension). The role of ANP in the development of hypertension has 
been examined in these rats, although not as extensively as in the SHR. 
In contrast to the SHR rat and  WKY control rats, Dahl-S rats have been 
shown to have higher ANP concentration In their atria (Snajdar & Rapp 
1985), than Dahl-R rats. Snajdar & Rapp (1985), reported that in young 
rats (1-2 month), the ANP content of the heart was higher in Dahl-S than 
Dahl-R rats w ith small differences in BP, (113 ± 2.9 mmHg and 103 ±2.1 
m m Hg respectively). In addition, in older rats (7 month) where the BP 
differences were greater between Dahl-S and Dahl-R rats, (234 ±7.1 mmHg
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and 130 ±2.3 mmHg respectively), ANP in the atria still remained higher 
in Dahl-S rats than in Dahl-R rats. Alterations of diet from normal, 1% 
salt-chow to low, 0.3% or high, 8% salt-chow did not affect this difference. 
An 8% salt diet equally suppressed the ANP atrial content of both strains. 
Snajdar and Rapp (1985) also reported renal hypo-responsiveness to ANP 
in 1 m onth pre-hypertensive Dahl-S rats compared to age-matched Dahl- 
R rats. In contrast how ever as the rats aged (7 m onth) and became 
m arkedly hypertensive Dahl-S rats showed hyper-responsiveness to ANP 
compared to age-matched Dahl-R rats. In 1986, Schwartz et a l (1986) and 
G utkw oska et aï. (1986) investigated the effects of salt diet on BP and 
plasm a ANP concentration in Dahl rats. Both of these groups reported 
that Dahl-S rats fed on a high salt diet, (5 weeks on 8% salt) have a higher 
blood pressure and higher plasma ANP concentration than Dahl-R rats, 
on the same diet. Snajdar & Rapp (1986), further examined the effects of 
age and diet on Dahl-S and Dahl-R rats. In this study Dahl-S and Dahl-R 
rats (2 m onth of age) on a normal salt diet again showed small differences 
in BP (119 ± 3.6 m m Hg and 111 ± 2.6 m mHg respectively) w ith no 
statistical differences in plasma ANP concentration (222 ± 22.2 p g /m l and 
251 ± 20.3 p g /m l respectively). In contrast to this, 6 m onth old Dahl-S rats 
showed increased BP when compared to Dahl-R rats, 199 ± 5.3 mmHg and 
119 ± 2 m mHg respectively and increased plasm a ANP concentration, 
1079 ± 259.3 p g /m l and 242 ± 34.4 p g /m l respectively. Snajdar & Rapp
(1986) also showed that changes of a similar order could be induced in 
young, 6 week old Dahl-S fed on a high salt diet for 3 weeks, compared to 
age-m atched Dahl-R rats on the sam e diet. These high plasma ANP 
concentration were interpreted as a response to hypertension and not a 
cause of hypertension.
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In 1987, Hinko et al. (1987) examined the binding characteristics of ANP 
and the production of cGMP in the kidneys of Dahl-S and Dahl-R rats, on 
low (0.15%) or high (8%) salt diets. ANP dissociation rates from kidney 
membranes were similar for Dahl-S and Dahl-R rats on the low salt diet. 
However, there was a decrease in ANP dissociation rate in the Dahl-R rats 
with no change in the Dahl-S rats on high salt diets. Receptor density was 
similar between the two strains of rats on both high and low salt dietary 
regimes. This group observed that basal renal cGMP production levels 
were higher in Dahl-S than  in Dahl-R rats. However ANP-stimulated 
renal cGMP generation w as similar between Dahl-S and Dahl-R rats 
independent of the dietary regime. From these results Hinko et al. (1987) 
speculated that the renal receptor of Dahl-R rats which showed salt- 
induced alterations in ANP dissociation rates was most likely the ANP-C 
receptor.
The above results indicate that in Dahl-S rats atrial ANP content is 
increased when compared to Dahl-R rats. This change in ANP content 
between the two strains of rat is independent of age and dietary regime (a 
high salt diet suppresses atrial ANP content equally in both strains of 
rats). Î Snajdar & Rapp (1985) speculated that the higher atrial ANP 
content of Dahl-S rats compared to Dahl-R rats may be due to a defect in 
the ANP secretory mechanism of Dahl-S rats. This would be reflected in 
decreases in plasm a ANP concentration and increases in BP in Dahl-S 
rats. Onwhochei & Rapp (1989) supported this speculation and showed 
that a deficiency in ANP release from the atria occurs at an early stage in 
the development of hypertension and may contribute to the progressive 
hypertensive state in Dahl-S rats, (as Ferrier et ah 1988 and Tunny et al. 
1986 found in the human). . In addition Snajdar & Rapp (1985) speculated
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th a t the hypo-responsiveness of the kidney to ANP in the p re ­
hypertensive Dahl-S rats w ould result in increases in BP and increases in 
plasm a ANP concentration. Age and a high salt regime were shown to 
cause m arked increases in BP and also showed increases in plasma ANP 
concentration in Dahl-S rats w hen compared to the equivalent Dahl-R 
rats (Snajdar & Rapp 1986). Therefore, in the Dahl-S rat there may be two 
genetic defects mediating the effects of ANP; one involving the synthesis, 
storage and release of ANP and one involving the kidney and its 
response, Snajdar & Rapp (1985).
1.4.4 Surgically manipulated models for Hypertension
1.4.4.1 The Renal hypertensive rat
Goldblatt and co-workers (Goldblatt et al. 1934) were the first to produce a 
reliable model in dogs, of renovascular hypertension by constriction of a 
main renal artery following surgery. The initial effect of this constriction 
is reduced renal arterial pressure, however w ithin a few m inutes the 
systemic arterial pressure begins to rise and continues to do so. Once the 
systemic arterial pressure reaches a new stable pressure level the renal 
arterial pressure returns alm ost to normal (Guyton 1976). Hypertension 
induced by the constriction of one renal artery while the other kidney is 
left untouched is referred to as the two-kidney, one-clip, (2K-1C) model. 
H ypertension induced by the constriction of one renal artery while the 
other kidney is removed is referred to as the one-kidney, one-clip, (IK-IC) 
model. The IK-IC rat at 4 weeks of developed hypertension has normal 
renin concentrations and volume expansion is present. The 2K-1C rat at 
an  equivalent stage of hypertension has elevated renin concentrations 
and there is no evidence of volume expansion (Davis 1977). Garcia et al.
(1987) observed in the 2K-1C and IK-IC rat models increases in plasma
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ANP concentration w hich correlated well w ith cardiac weight. They 
speculated that once the  ventricles become hypertrophic they m ay 
participate in ANP release. Lattion et al. (1990) examined the influence of 
sodium (for 3wk) in IK-IC ra t model and found that animals receiving a 
regular sodium diet, (0.27%) show ed increases in ANP-specific mRNA in 
right and left atria com pared to salt-restricted, (0.006%) animals. Schiffrin 
(1989) showed that vascular ANP receptor sites in the IK-IC and in the 
2K-1C rat models, varied inversely with plasma ANP concentration, i.e. 
an increase in plasma ANP concentration and a decrease in ANP receptor 
density.
1.4.4.2 The Deoxycorticosterone acetate (DOCA)-salt hypertensive rat 
Seyle and colleagues (Seyle et al. 1943) were the first to observe that 
deoxycorticosterone aceta te  (DOCA), a m ineralocorticoid agonist, 
combined with high salt d iet elicited a hypertensive-like syndrom e in 
rats. The (DOCA)-salt hypertensive model is now widely studied  to 
elucidate the precise action of m ineralocorticoids in experim ental 
hypertension.
Nuglozeh et al. (1990) examined the regulation of receptors for ANP in 
the renal papilla of the DOCA-salt hypertensive rat. They reported that 
there was an increase, (141 ± 31 compared to 34 ± 8 fm ol/papilla) in 
receptor density, (only a 125 kDa receptor was present) in the DOCA-salt 
hypertensive rat compared to controls. However the receptor affinity was 
sim ilar. The plasm a ANP concentration w as increased, (408 ± 35 
compared to 133 ± 12 p g /m l) w ith a suppressed plasma renin activity, 
compared to controls. The production of cGMP in the renal papilla in 
response to ANP w as higher in DOCA-salt rats than in controls. In
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density, (in both ANP-B and ANP-C receptors). Thus renal papillary ANP 
receptors of the DOCA-salt rat are increased and vascular and glomerular 
ANP receptors are decreased compared to controls. In 1987, Morton et al.
(1987) and Schiffrin & St-Louis (1987) showed an increase in plasma ANP 
concentration and a decrease in mesenteric artery vascular ANP receptor 
density in DOCA-salt rats compared to control rats. In 1989, Schiffrin 
(1989) also showed that blood vessel vascular ANP receptor sites in the 
DOCA-salt ra t varied  inversely  w ith  p lasm a ANP concentration 
compared to controls.
1.4.5 Summary
In summary, the precise effect of alterations in salt diet on ANP receptor 
density in the experimental rat models of hypertension is controversial. 
In general plasma ANP concentration is increased and atrial ANP content 
decreased, (with the exception of Dahl-S rats where both plasma ANP 
concentration and atrial AN P content are increased, when compared to 
Dahl-R rats). In animal models such as Dahl rats there is evidence that a 
deficiency in ANP secretion early in hypertension (as reported for man by 
Ferrier et al. 1988 and Tunny et al. 1986) may promote the development of 
hypertension. The exact relationship between receptor density, cGMP 
levels, alterations in salt d iet and experimental hypertension in various 
tissues remains uncertain.
1.4.6 Objectives
Two ANP-specific receptors, most likely the ANP-B and ANP-C receptors 
have  p rev iously  been repo rted  in ra t  sarcolem m al m em brane 
preparations (Rugg et al. 1989). As an extension of this work, experiments 
described in this thesis were aimed at the determination of density (Bmax)/ 
population (ANP-C or ANP-B receptors), molecular size and affinity (K<j)
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of ANP-specific receptors in  bovine ventricular cardiac sarcolemm al 
m em branes.
Further experimental work presented in this thesis forms part of an on­
going investigation in this laboratory to assess the effects of dietary salt 
regim e on plasm a ANP concentration, ANP-specific receptor b inding 
kinetics and  ANP-specific recep tor gene expression in the Dahl 
hypertension resistant (Dahl-R) and Dahl hypertension sensitive (Dahl-S) 
rat. Partially purified liver plasm a m em brane homogenates of male 
Dahl-R and Dahl-S rats were investigated to assess the effects of resistance 
and sensitivity  to hypertension, in conjunction with a variation in 
dietary salt regime on population, density, affinity and guanylate cyclase 
activity of ANP receptors in this tissue. In addition, studies of partially 
purified liver plasm a membrane hom ogenates of the W istar rat were 
carried out to determine the population, density, affinity and guanylate 
cyclase activity of ANP receptors in this rat.
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CHAPTER 2
MATERIALS AND METHODS
12,1 Materials.
Rat a-ANPi_28 was purchased from Sigma , Poole, Dorset., and also from 
Biomac, Glasgow University, Glasgow. Des [QSGLG] ANP (4-23)-NH2 was 
from Cambridge Research Biochemicals, Cambridge and [Tyr^] ANP (5-27) 
was obtained from Peninsula Laboratories, St., Helens. [125i]-anP (rat a - 
ANPi_2s; specific activity 2200 Ci/m m ol) was obtained from N E N /D u 
Pont (U.K.) Ltd. Stevenage, Herts and and Na^^Sj (specific activity 
17Ci/m g; pH  8-10) was obtained from Amersham International pic, 
Amersham, U.K. Disuccinim ydyl suberate (DSS), ethylene glycol bis 
(su c c in im id y lsu c c in a te ) (EGS) and  N -h y d ro x y su cc in im id y l-4 - 
azidobenzoate (HSAB) were obtained from Pierce Chemicals U.K., Life 
Science Labs., Luton, U.K. All other biochemicals were obtained from 
Sigma, Poole, Dorset, U.K. All general reagents were of analytical grade 
and supplied by BDH, Poole, Dorset U.K.
The antibody to cGMP was a gift from Dr. P. Hamet (Clinical Research 
Institute, Montreal, Canada).
Rats (Wistar) were obtained from the University of St. A ndrew s stocks. 
These animals were m aintained under a 12 h day/n ight cycle and allowed 
free access to food.
4 8
Rats (Dahl) were obtained from  M ollegaard Breeding Center Ltd., 
Tornbjergvej 40, Ejby, DK 4623 LI. Skensved, Denmark. There were two 
strains of Dahl rats. One which is resistant to a salt-induced hypertensive 
state and one which is sensitive to a salt-induced hypertensive state.
Original genetic traits were m aintained by brother x sister mating of stock 
rats and subsequent litters were used for experimental analysis.
At 5 weeks of age the rats were all allowed free access to food (R & M 1 
Cube Diet containing 0.8% NaCl) and  then after 10 days the rats were split 
into groups which continued on a norm al diet (0 .8 % NaCl) and groups 
which were given access to food (m odified R & M 1 Cube Diet containing 
8% NaCl). The rats were heparinised after a further 5 weeks with 1 m l/K g 
of 5000 u n its /m l i.e. 5000 u n its /K g  intra peritoneal and killed by 
decapitation following ether anaesthesia and their tissues rem oved and 
frozen in liquid N% and stored at - 90 until required.
2.2 Blood Pressure Determination.
Arterial blood pressure was m easured in animals from each group i.e. (a) 
Dahl-R on normal salt-diet (b) Dahl-R on high salt-diet (c) Dahl-S on 
norm al salt-diet and  (d) Dahl-S on  high salt-diet. P ressures were 
m easured utilising an Apollo M odel 179 Blood Pressure Analyser (IITC, 
Life Sciences USA). Briefly, rats w ere handled and introduced to the tail 
cuff apparatus for a period of approxim ately 2 weeks to reduce any 
possibility of stress related to the equipment. Rats were then weighed 
prior to blood pressure monitoring, w ith a minimum of 3 separate groups 
of readings taken every week over a 4 week period. (The blood pressure 
results in Chapter 4 were measured on 3-4 occasions over the last 10 days
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of the dietary regime). During the measurements the anim als were kept 
at a constant tem perature of 28-29 °C (temperatures any higher tended to 
cause heat stress).
2,3 Membrane Preparation.
2.3.1 Bovine sarcolemmal membranes.
Bovine hearts were obtained fresh from a local abbatoir and immediately 
placed in ice cold phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 1.47 mM KH2PO4 and 8.1 mM Na2HP0 4 , pH  7.4). The ventricle was 
m inced finely in a food processor, added to 10 vol. (40 g /200  ml) 
hom ogenisation buffer A (1 mM NaHCOg pH  8.0, containing 0.5 mM 
d ith io th re ito l, (DTT), 0.18 m g /m l pheny lm ethy lsu lphony lfluoride, 
(PMSF) and 0.1% bacitracin) and homogenised w ith  a Polytron PT-10 in 
slurry volumes of 200 m l for 6 x 20 s bursts at setting 5. The resulting 
riomogenates were then diluted 2:1 with salt extraction buffer B (1 mM 
N aH C O s, 1.2 M KCl, 100 mM Na4P2 0 y, 5 mM M gCb, 0.5 mM DTT, 0.18 
m g /m l PMSF, 0.1% bacitracin, pH  8.0) and stirred slowly for 45 min at 4 °C 
a^d  then centrifuged a t 31,360 gav for 30 min at 4°C, (Beckman J21, Type 
JA.20 fixed angle rotor). The supernatant was discarded and the pellet 
resuspended to the initial hom ogenising volume (200 ml) w ith 1 mM 
N aH C O a, 25 mM N a4P 2 0 y, 2.5 mM MgCl2, 0.5 mM DTT, 0.18 m g/m l 
PMSF, 1 |xM leupeptin , 0.1 pM pepstatin, 1 pM apro tin in  and 0.1%
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bjacitradn, pH  8.0 (buffer C) and recentrifuged at 31,360 gav for 30 min at 
46c . The resulting pellet w as resuspended to the initial volum e with 
buffer C which also contained 33% glycerol and then stored in 50 ml 
aliquots at - 9(PC for up  to a maximum of 8 weeks. Purified sarcolemmal 
m em brane fractions w ere obtained as described by Cramb & Dow (1983). 
Briefly, 100 ml of the glycerol frozen samples were thawed and m ade up to
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320 ml with 1 mM NaHCOa, 25 mM Na4P207 , 2.5 mM M gC^, 0.5 mM DTT 
and 0.1% bacitracin and centrifuged at 31,360 gav for 30 min at 4°C. The 
resulting pellets were resuspended in 30 ml of 5 mM Hepes buffer pH 7.4 
containing 0.5 mM DTT to which was added 45 ml 5 mM Hepes pH  7.4 
containing 67% (w /v )  sucrose and 0.5 mM DTT to give a final 
concentration of 40% (w /v ) sucrose. A 10 ml cushion of 60% (w /v) 
sucrose in 5 mM Hepes pH  7.4 containing 0.5 mM DTT was overlaid with 
18.75 ml of the membrane suspension (40% w /v ), 6 ml of 5 mM Hepes pH
7.4 containing of 35% (w /v) sucrose and 0.5 mM DTT and 5 ml of 5 mM 
Hepes buffer pH 7.4 containing 0.5 mM DTT. The discontinuous sucrose 
gradients were centrifuged at 100,000 gav for 2 hr at 4^C (Beckman L7, 
SW28 rotor). The band  form ed at the 0/35%  sucrose interface was 
collected diluted with 40 ml 5 mM Hepes, pH  7.4 containing 0.5 mM DTT, 
and centrifuged at 31,360 gav for 30 min at 4°C. The resulting pellet was 
resuspended in 1-2 ml 5 mM Hepes, pH  7.4, 250 mM sucrose containing 0.5 
mM DTT, and stored at -20 ^C. The membranes were diluted to use at a 
final protein concentration of 10-25 pg /m l in radio-receptor and guanylate 
cyclase assays and 500-700 p g /m l in radio-receptor crosslinking assays.
2.3.2 Partially purified plasm a membrane homogenates of rat liver.
The livers from male Dahl-Resistant and male Dahl-Sensitive rats (230- 
350 g) were removed, weighed and immediately placed in liquid N 2 before 
subsequent storage at - 90 until required. For membrane preparation 
frozen samples were placed in 80 ml homogenisation buffer (25 mM Tris, 
0.25 M sucrose pH  7.4, containing 0.5 mM DTT, 0.18 m g/m l PMSF, 1 pM 
leupeptin , 0.1 pM pepsta tin  and 0.1% bacitracin) m inced finely with 
scissors and homogenised w ith a Polytron PT-10, 6 x 20 s bursts at setting 5. 
The resulting hom ogenate was then centrifuged at 666 gav for 10 min
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(Beckman J21, Type JA.20 fixed angle rotor). The supernatant was 
recovered and recentrifuged at 31,360 gav for 30 min at 4®C. The resulting 
pellet was then resuspended in 20 ml of buffer 1, (25 mM Tris, 0.25 M 
sucrose, pH  7.4, containing 0,5 mM DTT, 0.18mg/ml), and 40 ml of a 60% 
(w /v ) sucrose solution containing 25 mM Tris pH  7.4, 0.5 mM DTT and 
0.18 m g /m l PMSF, to give a final concentration of 43% sucrose. This 
solution was divided between two 40 ml tubes and overlaid with 10 ml of 
buffer 1 (8% (w /v) sucrose). The sucrose gradients were centrifuged at
100.000 gav for 2 h r at 4°C (Beckman L7, SW28 rotor). The plasma 
m em brane fraction formed at the 8%/43% interface was collected, diluted 
w ith 40 ml buffer 1 and centrifuged at 31,360 gav for 45 min at 4°C. The 
resulting pellet was resuspended in 2-3 ml buffer 1 and stored at - 20 °C. 
The membranes were diluted to use at a final protein concentration of 10- 
25 p g /m l in all assays. Plasma membrane fractions were prepared from 
the livers of male W istar rats (250-350 g) as above without initial storage.
2.4 I]-ANP Radio-receptor assay.
2.4.1 Bovine sarcolemmal membranes.
Membranes (10-25 pg protein) were incubated over 1 to 6 h  at 4 °C, room 
tem perature or 37 in 50 mM Tris-HCl, 150 mM NaCl, 0.1 mM EDTA, 5 
mM MgCl2, pH  7.4 containing 0.1% BSA, 0.1% bacitracin, 1 pM leupeptin, 
0.1 pM pepstatin, 0.1 pM  phosphoram idon, 0.1 mM PMSF and 1 pM 
aprotinin (incubation buffer). The final volume was 200 pi. Total binding 
was determined in the presence of a fixed concentration of [125i]-anP 
(50pM). Specific b inding was calculated by subtraction of non-specific 
binding (determined in the presence of a fixed concentration of [I25j]-ANP 
(50pM) and O.lpM ANP) from the total binding. Membranes (10-25 pg 
protein) were also incubated for 1 h at room  tem perature in incubation
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buffer. Binding w as determ ined either in the presence of increasing 
concentrations of [^25i].aNP (2-800 pM), in the  presence or absence of 
unlabelled ANP (1 |iM), or in  the presence of a fixed concentration of 
[125i]_anp (50 pM) and  increasing concentrations of unlabelled ANP, des 
[QSGLG] ANP (4-23)-NH2 or [Tyi^l-ANP (5-27) (1 pM  -10 \xM), Incubations 
were term inated by the addition of 2 ml of ice cold wash buffer (50 mM 
Tris, 150 mM NaCl pH  7.4 at 4 oQ  containing 1% BSA. Bound [^25i]-aNP 
was separated from free by  rapid filtration through W hatman GF/C filters 
followed by three washes with 9 ml of wash buffer. To reduce non-specific 
b in d in g  of the rad io lab e l the filters w ere  p re-soaked  in 0 .3 % 
polyethyleneimine (PEI) for at least 12 h prior to use, (Brunks et ah 1983). 
Incubations were staggered and the total filtration time including the 
washes was less than 20 s. Radioactivity was determ ined in a Packard 
Prias gam m a counter. Scatchard analysis w as determ ined by the 
ENZFITTER softw are package (a non-linear regression data analysis 
programmme) for the IBM computer, Leatherbarrow (1987).
2.4.2 Partially purified plasma membrane homogenates of rat liver.
The binding assay w as carried out as described above for the bovine 
sarcolemmal m em branes.
2.5 [1251]-a n ?  Receptor crosslmking assay.
2.5.1 Bovine sarcolemmal membranes
Sarcolemmal m em branes (700 |xg protein) w ere incubated w ith 50 pM 
[125i]-aNP in the p resence or absence of various concentrations of 
unlabelled  ANP o r des [QSGLG] ANP (4-23)-NH2. for 1 h at room 
tem perature in 50 mM  T ris/H epes, 0.1 mM EDTA, 5 mM MgCl2, pH  7.4 
containing 0.1% BSA, 0.1% bacitracin. The incubation buffer for binding
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in these crosslinking experiments initially contained 50 mM Hepes buffer 
in the place of Tris buffer, since Tris buffer is reported to interfere with 
crosslinking (Pierce 1988). How ever the subsequent washing protocol 
used prior to crosslinking elim inated any interference from the Tris and 
results with both Tris and Hepes buffers were found to be the same. The 
final volume was 2 ml. Incubations were term inated by the addition of 3 
ml of ice-cold 50 mM K2HPO4/K H 2PO4 pH  7.4 and the membranes were 
pelleted by centrifugation at 59,200 gav for 15 min at 4 ^C. The pellet was 
w ashed once with 5 ml of 50 mM K2H P O 4 / K H 2P O 4 pH  7.4 and 
recentrifuged at 59,200 gav for 15 min at 4 °C. The membrane pellet was 
then resuspended in 2 ml of 50 mM K2HPO4/K H 2PO4 pH  7.4 containing 
0.1 mM disuccinimidyl suberate (DSS) and incubated for 40 min on ice. 
The crosslinking reaction was term inated by the addition of 1 M 
ammonium acetate to a final concentration of 50 mM and diluted to 5 ml 
with 50 mM K2HPO4/K H 2PO4 pH  7.4 and centrifuged at 59,200 gav for 15 
min at 4 °C. The pelleted m embranes were resuspended in 5 ml of 62.5 
mM Tris/H C l pH  6.8 and recentrifuged at 59,200 gav for 15 min at 4 ^C. 
This final pellet was used directly as a sample in SDS-PAGE.
N-hydroxysuccinimide (NHS) homobifunctional crosslinkers such as DSS, 
react with primary amine functions of epsilon (8) amine groups on lysine 
or available N-term inal amines. A t pH  7-9, the amino group on a 
particular ligand such as [i25i]_ANP undergoes nucleophilic attack of the 
NHS-ester to form a stable amide bond and release N-hydroxysuccinimide 
as a by-product (see fig. 2 .1).
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Figure 2.1
NHS Ester Reaction Scheme and the Structure of DSS
o o. o oII / — I pH 7-9 II — IR '-C -O -N ^ + R-NH.  ---- ► R'-C-N-R + H O -N ^cT  H ^O'
NHS Ester Reaction Scheme
? ?• V n|_ )N -0 -C-CHz- CH2- CH2- CH2- CH2- CH2-C-O-N J
OSS 
M.W. 368.35 
Length 11.4 X
2.5.2 Sodium  Dodecyl Sulphate PoIyAcrylamide Gel Electrophoresis. 
Electrophoresis was perform ed using  a 7,5% separating gel and the 
discontinuous buffer system of Laemmli (1970). Briefly, 27.2 ml of a 30% 
(w /v) stock acrylam ide solution containing 2.7% (w /w ) of the bis- 
acrylamide crosslinker was diluted to 7.5% acrylamide with 20 ml of 4 x 
separating gel buffer (1.5 M Tris-HCl, pH  8.8 containing 0.4% SDS) and 32.8 
ml of distilled water, total volum e of 80 ml. The crosslinking agents, 
amm onium  persulphate (320 \il of 10% solution) and TEMED (120 pi) 
were added and the gel solution poured between two (16 x 16.8 cm) glass 
plates separated by 3mm spacers and the solution allowed to polymerize. 
A stacking gel of 4.5% was also prepared; 3 ml of a 30% (w /v) stock 
acrylamide containing 2.7% (w /w ) of the bis-acrylamide crosslinker was 
diluted to 4.5% acrylamide w ith 5 ml of 4 x stacking gel buffer (0.5M Tris- 
HCl, pH  6.8 containing 0.4% SDS) and 12 ml of distilled water, total 
volume of 20 ml. The crosslinking agents, ammonium persulphate (160 
pi of 10% solution) and TEMED (60 pi) were added and the gel solution 
layered on top of the 7.5% polym erized gel. A 3 mm thick, 20 toothed 
comb was placed in the 4.5% acrylam ide solution and polym erization 
allowed to occur. The com pleted gel system  was clamped into the 
electrophoresis apparatus and reservoir buffer (0.192 M Glycine, 0.025 M 
Tris, 0.1 % SDS, pH  8.3) added to the upper and lower chambers. The comb 
was rem oved and protein samples were loaded into the wells. The gel 
system was then linked to a power pack and run  under a constant voltage 
of 200 V (running time 2-3 h). Gels w ere finally rem oved from the 
apparatus stained with (Coomassie Blue-R 0.1% w /v , methanol 25% v /v , 
acetic acid 10% v /v  and H2O 65% v /v )  and destained with (methanol 50% 
v /v , acetic acid 10% v /v  and H 2O 40% v /v ).
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The relative mobility (Rf) of a protein which is logarithmetically related to 
the molecular weight can be calculated by dividing the distance of the 
protein migration by the distance of the tracking dye migration. (A typical 
calibration curve for SDS-PAGE m olecular weight markers is shown in 
figure 2.2 b. Estimates of the molecular weight of unknowm proteins can 
be made from the calibration curve).
2.5.3 SDS-PAGE of bovine sarcolemmal membranes.
The resulting pellets from the cross linking reaction were suspended in 
200 pi distilled water and diluted 1 : 1 w ith double strength sample buffer 
(125 mM Tris-HCl, 4.6% SDS, 8 M Urea, 0,002% bromophenol blue, pH  6 .8) 
in the presence or in the absence of 10% (v/v) P-m ercaptoethanol and  
boiled for 5 min. The equivalent of 230 pg of protein was loaded onto 
each lane of the gel and run as above. Gels were stained and destained as 
above. Gels were then stored in Philips 18 x 24 cm Ultra cassettes at - 20 ^C 
for 7-14 days with Amersham H yper film-MP, preflashed to increase the 
sensitivity of the film (the flash gun was set at a power ratio of ^ / i 6 and 
used at a distance of 6 feet in the presence of a Kodak No. 22 w ratten 
gelatin  filter). A utoradiographs w ere developed after 7-14 days. 
A utoradiographs and SDS-PAGE gels w ere finally scanned utilising a 
Shim adzu M odel CS-9000 D ual-W avelength  Flying-Spot Scanner, 
(Shimadzu Corporation, Kyoto, Japan). Autoradiographs and SDS-PAGE 
gel standard molecular weight m arkers were scanned at wavelengths of 
650 nm and 590 nm  respectively (a representative scan of an SDS-PAGE 
gel with molecular weight markers of 200, 116, 97.4, 66, 45 and 29 kDa is 
shown in fig. 2.2 a). The area under the peak is representative of the 
in tensity  of Coom assie Blue-R sta in  on the gel and reflects the 
concentrations of the individual proteins loaded onto the gel.
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Figure 2.2
A representative scan of SDS-PAGE m olecular weight standard m arkers 
and a typical calibration curve.
a) A representative scan of SDS-PAGE molecular weight standards from 
the scanning densitom eter. The indicated peaks are the appropriate 
m olecular w eight standard positions w ith  ^ indicating the start of the 
resolving gel and 2 indicating the position of the dye front.
b) A calibration curve of the the relative mobility of SDS-PAGE molecular 
weight standards. The molecular weight of unknown proteins can be 
calculated from this curve, (line fitted by eye).
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2.5.4 [125i ]->vNP crosslinkîng assay and SDS-PAGE of partially  purified  
plasm a m em branes isolated from rat liver.
The [125i ]-a NP  receptor crosslinking assay and SDS-PAGE was carried out 
as described above for the bovine sarcolemmal membranes.
2.6 M easurem ent of Guanylate Cyclase Activity.
2.6.1 Guanylate cyclase assay.
Guanylate cyclase activity was m easured in bovine cardiac sarcolemmal 
membranes and rat liver plasma membranes as follows. M embranes were 
incubated in the presence of 50 mM triethanolamine, pH  7.4, 1 mM GTP, 3 
mM  M nCl2, 2 mM IBMX, 10 mM theophylline, 0.1 m g /m l creatine 
phosphokinase and 5 mM creatine phosphate for 20 m in at 37 °C, in a 
final assay volume of 100 jil, which also contained ANP, des-ANP, Tyr^- 
ANP (1 pM- 1 |iM) or buffer, (for basal levels). Incubations were initiated 
by the addition of GTP and the final protein concentration was 10 pg /tube  
for both membrane preparations. Incubations were term inated by the 
addition of 1 ml of 30 mM EDTA at greater than 90°C and the solution 
assayed for cGMP by radioim m unoassay. To ensure there was no 
interference of reagents with the subsequent cGMP assay, zero time points 
were prepared which contained all of the reagents and the membranes but 
were not incubated.
2.6.2 Radioimmunoassay for cGMP,
cGMP was determined by radioimmunoassay as described by Richman et 
al. (1980). Duplicate 100 pi samples of buffer, standard or unknown were 
placed in Sterlin RT 30 tubes followed by 100 pi of [l25i]>ScGMP-TME 
(10,000-15,000 cpm/100 pi, see below) and 250 pi of the cGMP antibody, 
(diluted 1 : 45,000). The [l25i].ScGMP-TME and the cGMP Ab were both
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prepared in 50 m M  sodium acetate pH  4.75 containing 0.5% BSA, as were 
the standards. The reagents were allowed to equilibrate by incubation 
overnight (15 - 24 h) at 4 °C. The Ab was precipitated by the addition of 2 
ml of cold 96% ethanol. The tubes were vortexed and allowed to stand at 
room tem perature for 30 min. The resulting precipitate was pelleted at 
1,500 g for 30 m in a t 4 °C (Fisons Coolspin Centrifuge) and the supernatant 
removed by aspiration. Radioactivity of the pellet was determined by a 
Packard Prias gamm a counter.
For each experiment a standard curve in the range of 0.0625-8 pmol/100 pi 
cGMP was prepared. Non-specific binding was defined as the radioactivity 
bound in the presence of excess cGMP (20 nmol) and was subtracted from 
all values. Results were expressed as counts bound in the absence (zero 
standard) of cGMP (Co) divided by the counts bound in the presence of 
cGMP (Cx). A plot of ^®/cx against cGMP concentration produced a 
s tandard  curve from  which the am ount of cGMP in each sam ple 
(unknown) was estimated, (see fig 2.3 a).
2.6.3 Preparation of p25i]-Xyrosine M ethyl Ester Succinyl-cGMP. 
Succinyl-cGMP tyrosine methyl ester (ScGMP-TME) was labelled with [I25i] 
according to the m ethod described by  Richman et a l (1980). Briefly, 20 pi 
of ScGMP-TME (2 pg) and 10 pi of Na 125% (approx. 1 mCi) were placed in a
1.5 ml microfuge tube and the reaction initiated by the addition of 20 pi 
chloramine-T (1 m g /m l in 50 mM potassium  phosphate buffer pH  7.4). 
The reaction w as term inated after 45 s by the addition of 50 pi of sodium 
m etabisulphite (1 m g /m l in 50 mM potassium  phosphate buffer pH  7.4). 
Sodium iodide (100 pi of 5 mM) w as then added to reduce the specific 
activity of the unreacted [125%] and to dilute the ionic strength to less than
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Figure 2.3
M easurement of cGMP b y  Radioimmunoassay (RIA)
(a) A representative standard  curve for the assay of cGMP. Each point is 
the mean ± S.D. of three determinations, (b) A plot of radioactivity bound 
against cGMP concentration. (Lines fitted by eye, errors less than 1% of 
each value).
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250 mM. The reaction mix was layered on top of a QAE-25 Sephadex 
colum n w hich h ad  been pre-equilibrated  w ith  50 mM am m onium  
formate, pH  6 a t 4 ®C. The reaction mix was allowed to run  into the 
column and was then washed with approxim ately 300 pi of 250 mM 
ammonium formate, pH  6 at 4 oC. The [i25i]-Sc-cGMP was eluted with 250 
mM ammonium formate, pH  6 at 4 °C, at a flow rate of 1 m l/m in  at 4 °C. 
Fractions of 2 ml were collected and 5 pi aliquots from these were counted 
for radioactivity. Fractions corresponding to peaks in radioactivity were 
diluted to 15,000 cpm/100 pi and assayed for their binding to the cGMP Ab. 
The fractions containing the highest binding were pooled and stored in 
200 pi aliquots at - 20 ®C, (see fig 2,4).
2.7 Protein Assay.
Protein  concentrations w ere determ ined  using  B radfords pro te in  
estimation solution, (Bradford 1976). Bradfords solution was prepared as 
follows; 100 mg of Coomassie Blue-G250 was dissolved in 50 ml of 95% 
ethanol, 100 ml of 85% (w /v) orthophosphoric acid was added and the 
solution made up to 1 1 with distilled water. The final solution was ready 
for use after filtration with W hatm an N o.l filter paper. The protein 
standards, samples or buffer (100 pi) were added to 5 ml of Bradfords 
solution, mixed and allowed to stand at room tem perature for 2 min. The 
absorbance w as then  m easured at 595 nm  in a Philips PU 8620 
spectrophotometer. Bovine serum album in was used as a standard, (BSA 
at 1 m g/m l, m easured at 280 nm should give a value of 0.67), with sample 
buffer blanks and the assay was linear over the range 10-100 pg of protein. 
The protein  concentration of the sam ple was determ ined from the 
regression line of the standard curve for BSA, (see fig. 2.5).
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Figure 2.4
PuriJfication of p25i]-ScGMP-TME
Profile of radioactivity eluted from a QAE-25 Sephadex column. Fractions 
from peaks 1, 2 and 3 were assayed for cGMP antibody binding. The 
dashed area represents the fractions which were pooled to give [l25i]. 
ScGMP-TME for use in the cGMP assay.
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Figure 2.5
M easurem ent of protein using Bradford's protein assay.
A representative standard curve for the Bradford's protein assay. Each 
point represents a separate determ ination. Bovine serum  album in was 
used as the standard. The absorbance was measured at 595 nm.
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2 .8  Statistics
The data  in this thesis is p resented  as the mean ± S.D. (standard  
deviation), w ith the exception of the guanylate cyclase assays where the 
data is presented as the mean ± S.E.M. (standard error of the mean). 
Where there are no error bars indicated on graphs, the errors were less 
than 1% of the m ean value. Graphic lines were fitted by eye w ith the 
exception of the Scatchard analysis w here the lines were fitted by the 
ENZFITTER programmme for IBM p.c. Leatherbarrow (1987).
Statistical analysis in Chapter 4 w as determ ined using the S tudent’s 
unpaired t-test. The relative degrees of freedom and the probability values 
for each appropriate test are listed in Chapter 4.
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CHAPTERS
RESULTS AND DISCUSSION OF BOVINE VENTRICULAR 
SARCOLEMMAL MEMBRANE EXPERIMENTS
3.1 Introduction
Bovine ven tricu lar sarcolem m al m em branes (BS m em branes) w ere 
prepared as described in the M aterials and M ethods. Radio-receptor 
binding, radio-receptor crosslinking and guanylate cyclase assays, w ith 
ANP and  AN P analogues w ere carried  ou t on these m em brane 
preparations. From these assays the density (Bmax)/ population (ANP-C or 
ANP-B receptors) and affinity (Kj) of ANP specific receptors in bovine 
ventricular sarcolemmal membranes was determined.
3.2 p25i].ANP Radio-receptor Binding
3.2.1 Displacement of [^I]-A N P by ANP
Incubation of [i25i]-ANP with BS membranes at 4 °C (see fig. 3.1), 22 oc  (see 
fig. 3.2) and 37 ®C (see fig. 3.3) resulted in tim e-dependent increases in 
radioactivity. Specific binding, defined as that binding not displaced by 0.1 
pM ANP, reached a steady state w ithin 5 hr, 60 m in and 30 m in for 
experiments perform ed at 4 ®c, 22 and 37 °C respectively. The times 
required for half maximal specific binding ( t i /2) at 4 °C, 22 ^C, 37 °C were 
75 min, 12 min and 10 min respectively. Subsequent experiments were 
performed for 60 min at 22 °C. To assess the affinity and total density of 
[125i]-ANP binding sites in BS membranes a saturation binding curve was 
constructed from  three BS m em brane preparations w hich had been 
previously incubated with 0.005% TX-lOO for 15 min at 4 °C (see fig. 3.4 a). 
The presence of a maximum concentration of [i^^I]-ANP (1 nM) was not 
sufficient to saturate all of the ANP receptor population. A Scatchard plot
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Figure 3.1
Tim e course for the b in d in g  of [^25i ] .a n P to bov ine  v e n tricu la r
sarcolemmal m embranes at 4 °C.
[^25i]-ANP (50 pM) was incubated with BS membranes (25 pg/lOO pi) at 4 
°C, in the absence (0 -0 , total) and the presence (0 -0 , NSB) of 0.1 pM ANP. 
At the indicated times tube contents were filtered through W hatm an 
G F/C  filters as described in  the Materials and Methods. The specific 
binding (■-■) was calculated by subtraction of the NSB form the total 
binding. Each point represents the mean of at least 3 determ inations 
(errors less than 1% of each value), from a single preparation.
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Figure 3.2
Tim e course for the b in d in g  of [^^^IJ-ANP to bov ine  v en tricu la r
sarcolemmal m em branes at room  tem perature.
[125i]-ANP (50 pM) was incubated w ith BS membranes (25 pg/100 pi) at 
room tem perature in the absence (0 -0 , total) and the presence (□-□, NSB) 
of 0.1 p,M ANP. At the indicated times tube contents w ere filtered 
through W hatman G F/C  filters as described in the Materials and Methods. 
The specific binding (■-■) was calculated by subtraction of the NSB form 
the to tal binding. Each po in t represents the mean of at least 3 
determ inations (errors less than  1 % of each value), from  a single 
preparation.
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Figure 3.3
Tim e course for the  b in d in g  of to bov ine  v en tricu la r
sarcolemmal membranes at 37 °C.
[125i].a.NP (50 pM) was incubated with BS membranes (25 pg/lOO pi) at 37 
in the absence (0 -0 , total) and the presence (□-□, NSB) of O.lpM ANP. 
At the indicated times tube contents were filtered th rough  W hatman 
G F /C  filters as described in the Materials and Methods. The specific 
b inding (■-■) was calculated by subtraction of the NSB form the total 
binding. Each point represents the mean of at least 3 determ inations 
(errors less than 1% of each value), from a single preparation.
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of the data (see fig. 3.4 b) indicated the presence of only one receptor site 
with a Kd of 43.6 ± 8.28 pM  and a Bjnax of 48.5 ± 2.7 fm ol/m g protein. 
These results however do not ru le  out the possibility of other lower 
affinity sites in these membranes since saturation of all the binding sites 
was not achieved. (Due to expense, this experiment could not include any 
concentrations of [125i].anP  higher than 1 nM). The displacem ent of 
[125i]_anP (50 pM) by unlabelled ANP was measured in three separate 
preparations (see fig. 3.5 a). The data from these experim ents was 
combined and [125%]_ANP bound was expressed as a percentage of the 
m axim um  specific binding. The concentration of ANP required to 
produce a 50% inhibition of binding (IC50) was determined as 140 ± 60 pM. 
The displacement of [125i]_aNP (50 pM) by unlabelled ANP was also 
investigated in BS m em branes which had been previously solubilised 
with 0.1% TX-lOO (see fig. 3.5 b). This data provided an IC50 value of 40 
pM. Solubilisation of the m embranes did not increase the total specific 
binding of [i^Sjj-ANP, (45.92 ± 2.82 fm ol/m g (n = 1) as opposed to 59.22 ± 
35.99 fm ol/m g (n = 3) in the absence of TX-lOO treatment), thus suggesting 
that detergent action on the membranes did not allow [125i]-aNP access to 
an increased number of receptor sites. The displacement of [125i]_anP (50 
pM) by des-ANP and  Tyr®-ANP was also exam ined in separate BS 
membrane preparations (see figs. 3.5 c and d). The IC50 values for these 
analogues were determ ined as 1 pM and 1 nM respectively. Using the 
equation.
Kd
IC50
Kd — I C 5 0 / 1 +  ([HOT]/Kd (HOT))
is the dissociation constant for unlabelled ANP
is the concentration of ANP resulting in half maximum
displacement of radioligand
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Figure 3.4
S a tu ra tio n  curve for [^25%]_ANP b in d in g  to bo v in e  v e n tr ic u la r
sarcolemmal membranes. (Prior incubation w ith  0.005% TX-lOO).
(a) BS m em branes were incubated for 1 hr at 22 w ith increasing 
concentrations of [i25i]-ANP. NSB was determined in the presence of 1 pM 
ANP for each concentration of [125%]_ANP; specific binding w as then 
calculated by subtraction of the NSB from the total binding. Each point 
represents the mean of at least 3 determinations (errors less than 1% of 
each value), from three separate preparations.
(b) Scatchard plot of the combined data shown in (a) calculated using the 
ENZFITTER programme on IBM Computer.
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Figure 3.5
Inh ib ition  of b in d in g  in  bovine ven tricu lar sarcolem m al
membranes by  ANP, des-ANP and Tyr^-ANF.
Dose response curves for the displacement of [^25i ]>a NP  binding form BS 
m em branes (25 pg /100  pi) by (a) ANP, (b) ANP in solubilised BS 
m em branes, (c) des-ANP and  (d) Tyr®-ANP are show n. NSB was 
determ ined in the presence of 1 pM ANP for each curve and specific 
binding was then calculated by subtraction of the NSB form the total 
binding. Values are expressed as % of the maximum specific binding of 
[125i]_a n P and each point represents the mean of at least 3 determinations 
± S.D. Individual experiments were performed on separate preparations.
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[HOT] is the concentration of [^25i]-ANP used in the dissociation
experim ent
Kd (HOT) is the dissociation constant for [^25i].^^p calculated from the 
saturation experiments
the Kd values of the above experiments were calculated (see table 3.1). The 
Kd for ANP binding in BS membranes was calculated to be 65 ± 27.85 pM. 
Solubilisation of the membranes with 0.1% TX-lOO did not have any effect 
on the Bmax but did decrease the Kd for ANP by approximately 3-fold to
18.7 pM. The Kd for des-ANP in non-solubilised BS m em branes was 
calculated to be 486 nM, approximately 7000-fold higher than the Kd value 
for ANP and the calculated Kd value for Tyr^-ANP was approximately 7- 
fold higher than the value for ANP at 466 pM.
3.2.2 Displacement of p25i]-ANP by BNP
Hirata et al. (1988) have previously shown that BNP can bind to the same 
receptor site as ANP. The displacem ent of [^25 j],anP  (50 pM) by 
unlabelled BNP was therefore examined in a BS membrane preparations 
(see fig. 3.6). BNP was found to displace [^^^i]_anP in BS membranes with 
an IC50 value of 400 pM.
3,3 P^I]-A N P Receptor crosslinking experiments.
Initial experiments were performed to assess the ability of DSS to crosslink 
[i25i]-ANP to its receptor site(s) in BS membranes for Ih r at 22^C (see fig. 
3.7). These early experiments indicated the presence of two molecular 
w eight receptor b inding sites for ANP in BS m em branes. Scans of 
autoradiographs revealed that these sites had molecular weights of 60 kDa 
and 120 kDa. Large amounts of radiolabel were detected at the top of these 
autoradiographs indicating that crosslinked protein m aterial was not
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Table 3.1
Estimated IC50 values and calculated Kj values for the dissociation of 
[125i]-anP by ANP, des-ANP and Tyr®-ANP in BS membranes.
The IC5 0  values were estimated from Figs, 3.5a-3.5d
Peptide Estimated IC5 0  value Calculated value
ANPl 140 ± 60 pM 65 + 28.75 pM
ANP2 40 pM 18.7 pM
des-ANP 1 pM 486 nM
TyrS-ANP 1 nM 466 pM
1 Dissociation of [125i]-anP in BS membranes by ANP.
2 Dissociation of [125i]_a NP  in BS membranes by ANP, previously 
incubated for 15min with 0.1% TX-lOO.
Figure 3.6
In h ib itio n  of b in d in g  in  bovine ven tricu lar sarcolem m al
m em branes by BNP.
A representative dose response curve for the displacement of [125i]-aNP 
binding form BS m embranes (25 pg/100 pi) by BNP is shown. N on­
specific binding was determ ined in the presence of 0.1 pM BNP and 
specific binding was then calculated by subtraction of the NSB from the 
total binding. Values are expressed as % of the maximum specific binding 
of [i^^I]-A N P and each po in t represen ts the m ean of at least 3 
determinations ± S.D. from an individual preparation.
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Figure 3.7
Crosslinking of P^Sij-a NP to bovine ventricular sarcolemmal membranes 
at room temperature in the presence or absence of p-mercaptoethanoL
[125i ]-a NP  (50 pM) was incubated with BS membranes (700 pg) at room 
tem perature, in the absence (lanes a and c) and in the presence (lanes b 
and d) of 0.1 pM ANP. Lanes a and b are in the presence and lanes c and d 
are in the absence of p-m ercaptoethanol. M igration of the m olecular 
weight standards is indicated.
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entering the SDS-PAGE gel. Urea (4 M) was included in the sample buffer 
at this time to aid the entry of this radiolabelled protein material into the 
gel. Urea was noted to increase the amounts of radiolabel entering the 
gels however the am ounts of radiolabel present in wells with unlabelled 
ANP and [i25i]-ANP rem ained higher than in wells with [125i]-anP alone, 
(this resu lt w as constan tly  observed  th ro u g h o u t the rem aining  
crosslinking experim ents). C rosslinking of [125i]-aN P w ith  BS 
m em branes at 22 ®C (see figs. 3.8, 3.9 a and 3.9 b) resulted in time- 
dependent increases in radioactivity for both of these receptor sites. In 
addition crosslinking w ith [^^^Il-ANP and BS membranes at 4 °C for 6 hr 
was performed (see fig. 3.10). The displacement of [125l]-ANP (50 pM) at 22 
°C by unlabelled ANP was initially examined in the presence or the 
absence of p-mercaptoethanol (see fig 3.11). These results revealed that the 
radioactive signals from  both of these receptor sites were lost if the 
samples were reduced with p-mercaptoethanol prior to electrophoresis. 
Two-dimensional SDS-PAGE was then perform ed, (see fig. 3.12) under 
non-reducing conditions (1st dimension) and then reducing conditions 
(2nd dimension). Two radiolabelled proteins of 60 kDa and 120 kDa were 
apparent after electrophoresis in the first dimension with no radiolabelled 
proteins greater than 5 kDa present after electrophoresis in a second 
dimension. The dissociation of [125i]_anP (50 pM) at 22 °C by various 
concentrations of unlabelled ANP (see fig 3.13) and des-ANP (see fig. 3.14 a 
and 3.14 b) was then investigated in crosslinking experiments under non­
reducing conditions. The data from the scanned autoradiographs was 
expressed as a percentage of the maximum binding in the presence of 50 
pM [i25i]-ANP alone (see fig. 3.15). The appropriate IC50 values w ere 
determ ined for each peptide and for each receptor protein. The IC50 
values for ANP dissociation of [125%].ANP from the 120 kDa receptor 
protein and the 60 kDa receptor protein were 0.07 nM and 0.3 nM
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Figure 3.8
Tim e course for the crosslinking of to bovine ventricular
sarcolemmal m em branes at room temperature.
[125i ]-a NP  (50 pM) was incubated with BS membranes (700 pg) at room 
temperature, for 180 min, (lanes (a) and (b)) 60 min (lanes (c) and (d)) and 
10 min (lanes (e) and (f)). Lanes (a), (c) and (e) are in the presence of [125i]_ 
ANP and lanes (b), (d) and (f) are in the presence of [i25%]_ANP and 0.1 ^iM 
ANP. Migration of the molecular weight standards is indicated.
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Figure 3.9
Time course for the crosslinking of P^Sjj-a NF  to bovine ventricular 
sarcolemmal membrane 60 kDa, 120 kDa receptor proteins and SDS-PAGE 
gel ’well’ proteins.
[125i]-ANP (50 pM) was incubated with BS mem branes (700 |ig) at room 
temperature, for 10 min, 60 min and 180 min.
(a) shows the increase in crosslinking of [i25i]-ANP to the 60 kDa and the 
120 kDa receptor proteins with time.
(b) shows the increase in crosslinking of [I25i]-ANP in the well of the SDS- 
PAGE gel with time. The areas are the appropriate areas determined from 
the scanned autoradiograph of fig. 3.8.
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Figure 3.10
Crosslinking of [^^Sij.anF to bovine ventricular sarcolemmal M embranes 
for 6 h r at 4 °C in the absence or the presence of p-mercaptoethanol.
[1251]-a n P  (50 pM) was incubated with BS membranes (700 pg) at 4 for 6 
h in the absence (lanes e, f, g and h) or in the presence (lanes a, b, c and d) 
of p-mercaptoethanol. lanes a, c, e, and g are in the presence [125%]_ANP (50 
pM) and O.lpM ANP. Lanes b, d, f and h are in the presence of [i25i]-ANP 
(50 pM). Migration of the molecular weight standards is indicated.
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Figure 3.11
Displacement of crossliiüced [125%].ANP to bovine ventricular sarcolemmal 
m em branes at room  tem perature in  the presence or absence of P- 
m ercaptoethanol.
[125i]-anP (50 pM) was incubated with BS membranes (700 pg) at room 
temperature, in the absence (lanes g to 1) and in the presence (lanes a and 
f) of p-mercaptoethanol. Lanes a and g are in the presence of [^^Sjj-anP 
only. ANP at lO'^M (lanes b and h), 10"®M (lanes c and i), lO'^M (lanes d 
and j), 10'^OM (lanes e and k) and lO’l^M (lanes f and 1) is present in 
addition to [i25%]_ANP. Migration of the molecular weight standards is 
indicated.
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Figure 3.12
2-Dimensional SDS-PAGE of [^25%]_ANP crosslinked bovine ventricular
sarcolemmal m em branes
After [i25i]-ANP crosslinking, samples were subjected to two dimensional 
SDS-PAGE under non-reduced (1st. dimension) and then reduced (2nd. 
dimension) conditions. Migration of the molecular weight standards is 
indicated.
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Figure 3.13
Inhibition of p25%].ANP crosslinking to bovine ventricular sarcolemmal
membranes at room temperature in the presence of ANP.
[125i ]-a NP  (50 pM) was incubated with BS membranes (700 pg) at room 
temperature, in the absence (lanes a) and in the presence of lO'^M (lanes 
b), lO’^M (lanes c), lO-^^M (lanes d) lO 'IlM  (lanes e) and lO'i^M (lanes f) 
ANP. Migration of the molecular weight standards is indicated.
d»  #  •
K . * #
M|^  CkDa]
2 0 5
1 1 6
9 7 . 4
66
4 5
2 9
Figure 3.14 a
Inhibition of [^25j]_a n P crosslinking to bovine ventricular sarcolemmal
mem branes at room temperature by des-ANP.
[i25i]-ANP (50 pM) was incubated w ith bovine cardiac sarcolemmal 
membranes (700 pg) at room temperature, the absence (lanes a) and in the 
presence of lO'^M (lanes b), lO'^M (lanes c), 10"®M (lanes d) 10‘^M (lanes e) 
and 10'^ OM (lanes f) des-ANP. M igration of the m olecular w eight 
standards is indicated.
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Figure 3.14 b
Inh ib ition  o£ [125%].ANP crosslinking to bovine ventricular sarcolemmal
m em branes at room temperature by des-ANP.
[125i]-aNP (50 pM) was incubated with bovine cardiac sarcolemmal 
membranes (700 pg) at room temperature, in the absence (lanes a) and in 
the presence of lO'^M (lanes b), lO’^M (lanes c), lO'^^M (lanes d) lO 'IlM  
(lanes e) and 10'^2^  (lanes f) des-ANP. Migration of the molecular weight 
standards is indicated.
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Figure 3.15
Inhib ition  of [^25%]_ANP crosslinking to bovine ventricular sarcolemmal
mem branes at room temperature by ANP and des-ANP.
Dose response curves for the displacement of crosslinked [i25i]_ANP (50 
pM) from BS membranes by increasing concentrations of ANP (a) and des- 
ANP (b).
(a) the areas are the appropriate areas determ ined from the scanned 
autoradiograph of fig. 3.13 and (b) the areas are the appropriate combined 
areas determined from the scanned autoradiographs of figs. 3.14 a and 3.14 
b. Values are expressed as a % of the maximum crosslinked value from 
scanned autoradiographs of well (A -A ), 60 kDa receptor protein (□-□) and 
120 kDa receptor protein (0 -0 ).
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respectively. The IC50 values for des-ANP dissociation of [^^^Ij-ANP from 
the 120 kDa receptor protein and the 60 kDa receptor protein were 2 nM 
and 5 nM respectively. The EC50 values for the increases in radiolabel in 
the SDS-PAGE gel wells were 0.3 nM and 2 nM for ANP and des-ANP 
respectively.
3,4 Results of Guanylate Cyclase Experiments.
Incubation of BS membranes at 22 °C (see fig. 3,16) and 37 (see fig. 3.17) 
in the presence or the absence of 1 pM ANP resulted in time-dependent 
increases  in g u a n y la te  cyclase a c tiv ity  as d e te rm in e d  by 
radioimmunoassay for cGMP. The rate of cGMP production was constant 
for at least 20min, both in the presence and in the absence of ANP. The 
relative amount of cGMP production (nm ol/pg protein) was greater at 37 
°C than at 22 throughout the time courses. Subsequent experiments 
were performed for 20 min at 37 °C, The effects of ANP, des-ANP and 
Tyr^-ANP on guanylate cyclase activity in BS membranes were examined. 
M anganese-dependent guanylate cyclase activity was m easured in the |
presence of increasing concentrations of the peptides (see fig. 3.18). ANP, 
des-ANP and Tyr^-ANP were all capable of stimulating guanylate cyclase 
activity by 46-100% of basal values. Atrial natriuretic peptide (ANP), des- 
ANP and Tyr®-ANP stim ulated guanylate cyclase activity from basal 
values of 60, 96 and 96 pm ol/m in /m g  protein to values of 110, 146 and |
191 p m o l/m in /m g  protein respectively. The relative EC50 values for 
ANP, des-A N P and  Tyr^-ANP were 1 nM, 0,1-1 pM and 0.1 pM 
respectively.
3.5 Discussion
Analysis of the data from ligand binding experiments indicated the 
presence of a single high-affinity (K^ for [125i ]-ANP 43,6 ± 8.3 pM and IQ
65
I
Figure 3.16
Tim e course for the p roduction  of cGMF in  bovine ven tricu lar
sarcolemmal mem branes at room tem perature.
A representative time course for guanylate cyclase activity in the absence 
(□-□) and in the presence (■-■) of 1 pM ANP. The assay was conducted at 
room temperature as described in the Materials and Methods. Each point 
represen ts the m ean ± S.D. from  one experim ent w ith  trip licate 
determ inations of guanylate cyclase activity, followed by duplicate 
determinations of cGMP.
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Figure 3.17
Tim e Course for the p roduction  of cGMP in  bovine ven tricu lar
sarcolemmal membranes at 37 ®C.
A representative time course for guanylate cyclase activity in the absence 
(□-□) and in the presence (■-■) of 1 |iM ANP. The assay was conducted at 
37 °C as described in the Materials and Methods. Each point represents the 
m ean ± S.D. from one experim ent w ith triplicate determ inations of 
guanylate cyclase activity, followed by duplicate determinations of cGMP.
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Figure 3.18
Stim ulation of guanylate cyclase activity in  BS m em branes by ANF, des- 
ANP and Tyr«-ANF.
BS membranes (10 |xg/20 jil) were incubated at 37 for 20 min with 
Increasing concentrations of ANP (• - • ) , des-ANP (■-■) and Tyr^-ANP (O- 
O). Points for des-ANP and Tyr^-ANP represent the mean ± S.E.M. of six 
individual m easurements taken from one experiments and points for 
ANP represent the m ean ± S.E.M. of twelve individual m easurem ents 
taken from two separate experiments.
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for ANP 65 ± 27.9 pM) binding site in sarcolemmal membranes isolated 
from the bovine ventricular myocardium. The ANP receptor population 
was found to bind the ANP analogues des-ANP and Tyr^-ANP with a 7000 
and 7-fold lower affinity respectively than ANP. The calculated Kd‘s for 
ANP, ANP in TX-lOO trea ted  m em branes, des-ANP and  Tyr^-A N P 
(determined from IC50 values) were 65 pM, 18.6 pM, 486 nM and 466 pM 
respectively. The ANP-C receptor has been characterised in other tissues |
and has been shown to possess equal binding affinity to ANP as that of 
various ANP analogues, including des-ANP (Maack et al. 1987; Inagami et 
al. 1988 and Lewicki et al 1988). The binding results therefore indicate that 
the ANP-B receptor is the predom inant receptor population in BS 
membranes. The binding  of BNP to BS membranes w ith an affinity 
similar to that of ANP indicates that BNP is perhaps binding to the same 
receptor site as ANP as suggested in other tissues (Hirata et al. 1988; Song 
et al. 1988; Gelfand et al. 1991), how ever fu rther crosslinking and 
guanylate  cyclase analysis w ith  BNP is required  to support this 
observation. The presence of ANP-B receptors in BS mem branes is 
further indicated by the fact that guanylate cyclase activity was stimulated 
up to 2-fold by ANP. Surprisingly, des-ANP and Tyr^-ANP were both able 
to stimulate guanylate cyclase activity up to 1.5 to 2-fold in BS membranes 
however the concentrations required were in excess of 100 nM. The 
guanylate cyclase results obtained with Tyr^-ANP are in agreement with 
that of Budzik et al. (1987) who observed that although low concentrations 
of Tyr^-ANP possessed potent vasorelaxant properties the peptide lacked 
the ability to stimulate cGMP production, at these low concentrations. A 
poor correlation betw een ANP ligand binding and the  subsequent 
stimulation of guanylate cyclase was noted in BS membranes. The Kd 
values obtained for ANP, des-ANP and Tyr^-ANP binding were found to 
be 10-100 fold lower than the EC50 values required for activation of %
guanylate cyclase. Schenk et al. (1985a) in bovine aortic sm ooth muscle 
and endothelial cells and  Pandey et al. (1988) in rat aortic smooth muscle 
cells and kidney tubular epithelium  cells have previously reported similar 
discrepancies. The lack of correlation between these tw o values has 
previously been explained on the basis of ANP receptor heterogeneity and 
the predom inance of ANP-C receptors in the tissues or cells examined. 
However the second senario cannot be true of BS m em branes since the 
competitive displacem ent b inding  analysis with des-ANP indicated a 
predominance, greater than 90% of ANP-B receptors. It is possible that the 
relationship between the activation of guanylate cyclase activity and ANP 
ligand binding is more complex than was at first postulated. This has been 
recently indicated in ANP receptor cloning studies, w here a family of 
inter-related ANP receptor populations has been reported, (see section 
1.2.5.1).
Crosslinking studies in BS m embranes clearly indicated the presence of 
two receptor proteins, one of 60 kDa and one of 120 kDa in size, initially 
thought to be the ANP-C and ANP-B receptor populations respectively. 
The radioactive signals from  both of these receptor sites were lost if the 
samples were reduced w ith P-mercaptoethanol prior to electrophoresis. 
Pandey et al. (1987a; 1987b; 1988) and Takayanagi et al. (1987a) have 
reported the loss of all or nearly all of the radioactive signal from the 120- 
140 kDa receptor bu t not from  the 60-70 kDa receptor under sample 
reducing conditions. This result has been interpreted as indicative of the 
existence of a third ANP receptor, which possibly exists as a dimer of the 
ANP-C receptor and is reduced to half its molecular weight after treatment 
w ith  p-m ercaptoethanol or DTT. The unusual results found w ith BS 
membranes may indicate an alternative explanation. It is possible that the 
binding of [I25i]-ANP to both of these membrane receptors is associated
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w ith the hydrolysis of one or more of the peptide bonds w ithin the 17 
amino acid loop structure of the molecule. U nder non­
reducing conditions this w ould allow the ^^^I-radiolabeled tyrosine at the 
C-term inal of the [^25x]-a n P molecule to rem ain attached to the N- 
term inal of the [I^^iJ-a N P  molecule via the disulphide bond and thus 
rem ain  attached to the  recep tor itself. In the presence of p- 
mercaptoethanol the disulphide bond connection between the C-terminal 
and the N-term inal of the hydrolysed [^^SjJ-a NP  m olecule w ould be 
reduced and the radiolabelled C-terminal of the [^25j]_a n P molecule 
w ould  be lost from the ANP-receptor unit. These results with BS |
m em branes therefore indicate an alternative explanation for the loss of 
high molecular weight receptor radiolabel found in crosslinking studies in 
other tissues. Crosslinking experiments investigating the competition of 
[125i]-ANP with various concentrations of unlabelled ANP indicate that 
[^25i].anP binding is lost from both of the identified receptor proteins in a 
concentration dependent m anner and both possess sim ilar IC50 values. 
Surprisingly, crosslinking experiments investigating the competition of 
[^25i]_anP with the ANP analogue, des-ANP also indicate that [125%].ANP 
binding is lost from both receptor proteins w ith similar IC50 values and 
w ith values that were only 16-30 fold higher than those of ANP. This 
result was unexpected. It was thought that des-ANP w ould be able to I
com pete with [125i ]-a n P  binding at the 60 kDa ’ANP-C’ receptor and 
w ould be unable to compete with [^ 25i ]»a n P  binding at the 120 kDa 'ANP- 
B’ receptor in BS mem brane preparations. It has to be remembered that 
crosslinking efficiency is extremely low, as is evident from  the intense 
am ounts of radiolabel p resen t at the bottom  of the SDS-PAGE gel 
autoradiographs. This [^25i ]_a n P radiolabel binding is specific since lanes 
w ith [i25i]-ANP and unlabelled ANP show less radioactivity running at 
the dye front than lanes w ith [125i ]-ANP alone; however the DSS seems to
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be unable to crosslink this specific [I25i]-ANP radiolabel to its respective 
receptor protein. The precise efficiency of DSS in crosslinking [^^SjJ-a N P  
to each of these two individual receptor sites under SDS-PAGE conditions 
remains to be fully determ ined. These results can possibly be interpreted 
as follows; the crosslinker DSS in BS membrane preparations is unable to 
crosslink [^25i ]_a n P to the 120 kDa 'ANP-B* receptor and the 120 kDa 
receptor protein which was identified in these crosslinking experiments 
may be a dimer of the 60 kDa * ANP-C' receptor. Therefore des-ANP in the 
crosslinking experiments w as able to competitively displace [^25i ]_a n P 
from a 60 kDa A N P-C receptor and a 120 kDa * ANP-C receptor dimer. 
This hypothesis may also explain w hy in the crosslinking experiments the 
120 kDa ANP-B' receptor is not found to predominate over the 60 kDa 
'ANP-C receptor protein in BS membranes as would be expected from the 
results of the radio-receptor assays. The presence of the ANP-B receptor 
with associated guanylate cyclase activity is therefore only identified in 
radioreceptor binding and  guanylate  cyclase experim ents w here this 
receptor population is indicated as being in the majority.
The experiments described dem onstrate the presence of [^25i]_a]sjp 
receptors in purified bovine ventricular sarcolemmal preparations and 
ANP-stimulated guanylate cyclase activity in the same preparations. 
Results also provide biochemical evidence for the presence of a t least 
three different ANP populations of receptors in the bovine ventricle. 
Specific receptors for ANP were identified as having similar molecular 
weights and some sim ilar biochemical characteristics as ANP receptors 
identified in other tissues and cells, (see section 1.2.2). In addition, results 
extend earlier experim ental studies from this laboratory w here the 
presence of two affinity classes of ANP receptors were demonstrated in 
purified ra t cardiac sarcolem m al preparations, (Rugg et al. 1989); one
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receptor possessing AN P-stim ulated guanylate cyclase activity. ANP- 
stim ulation of in tracellu lar cGMP levels in isolated rat and rabbit 
ventricular myocytes (Alton & Cram b 1985; Cramb et al. 1987) has also 
been demonstrated in this laboratory. The concentration of ANP required 
to produce half maximal stimulation of cGMP in the bovine sarcolemma, 
is similar to the concentration required in the rat sarcolemma, however 
this concentration is approximately 10-fold less than that required for half 
maximal elevation of cGMP in intact rat or rabbit myocytes. Lang at al. 
(1985) and Gutkwoska et al. (1984) found that plasma ANP concentrations 
were 2-3 fold less than the half maximal value required for stimulation of 
guanylate cyclase activity. This discrepancy is most likely due to the rapid 
degradation  of ANP w hich occurs w hen ANP is incubated w ith  
ventricular myocytes, (Cramb et a l 1987). It should be noted that James et 
al. (1990) observed no ANP binding sites on either atrial or ventricular 
myocytes in rat and guinea-pig cultures. This group suggested that the 
conflicting evidence, w ith regards to the presence/absence of ANP binding 
sites in cardiac muscle was perhaps a result of problem s in preparing 
completely hom ogenous suspensions of cells from the heart and that the 
ANP receptors previously identified w ere in fact associated with non­
m uscle cells. M orkin & Ashford (1968) show ed that myocytes only 
constitute approxim ately 27% of the m yocardial cells w ith connective 
tissue cells (35%) and  blood vessel endothelial cells (38%) together 
constituting 73%. Leitman et al. (1986) using both radio-receptor assays 
and crosslinking experim ents showed in endothelial cells, that greater 
than 90% of the total ANP receptors were ANP-C receptors, whereas radio­
receptor assays in bovine sarcolemmal mem brane preparations, indicated 
tha t greater than 90% of the total ANP receptor density  were ANP-B 
receptors (McCartney et al. 1990). These results indicate that it is unlikely 
that the ANP receptors identified in bovine cardiac muscle preprarations
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are associated with non-muscle endothelial cells. Alternatively, James et 
al, (1990) suggested that the apparent absence of ANP binding sites on rat 
and guinea-pig cultured myocytes may have been a result of the culture 
conditions. Patterson and Chun (1974) and Mudge (1981) have previously 
shown that growth m edium  conditioned by non-neuronal cells can alter 
the phenotype of som e neurones in culture. A nother possibility, 
proposed by Rugg et al. (1988) is that ANP is rapidly degraded by a soluble, 
heat labile peptidase isolated from ventricular myocytes. The apparent 
absence of ANP binding sites on rat and guinea-pig cultured myocytes may I
then be a result of rapid proteolytic degradation of ANP and a subsequent 
lack of ANP-specific receptor binding. The presence of ANP binding sites 
in bovine sarcolemmal membrane preparations may then be a result of 
the use of a 'cocktail' of protease inhibitors which ultim ately prevents 
rapid proteolytic degredation of ANP and allows for ANP-specific receptor 
binding.
%
There is controversy concerning the vasorelaxant actions of ANP and the 
role of cGMP as the second messenger mediating these actions, (see section 
1.1,7.3). Deth et al. (1982) and Currie et al. (1983) have shown direct 
evidence of a rat atrial extract causing relaxation of aortic strips. The 
resu lts presented  indicate that in bovine ventricular sarcolemm al 
preparations, ANP stim ulates cGMP production. H ow  the resultant 
stimulation of cGMP by ANP acts in the heart is not as yet fully known.
However, work reported by George et al. (1970), George et al. (1973), Endoh 
(1979) and Lincoln & Keely, (1980) has shown a correlation between 
increased intracellular cGMP levels and force of contraction of ventricular 1
muscle. W atanabe & Besch, (1975) have shown that dibutyryl cGMP 
antagonises the positive contractile effect of isoprenaline. Therefore 4|
cGMP antagonises agonist-induced positive contractile effects, with little
4g
Alternatively, ANP receptors present on ventricular m uscle m ay form 
part of a negative feedback mechanism. ANP has been found to be present 
in ventricular muscle and this raises the possibility that the release of 
ANP from granules in the atria may modulate ventricular ANP gene 
expression and hence the release of ANP from the ventricles.
3.6 Summary
The above radioreceptor binding data indicates in bovine ventricular 
sarcolem m al m em branes the presence of only one ANP receptor 
population/class/subtype, the ANP-B receptor. In addition there is poor 
correlation between the calculated dissociation constant for ANP and the 
half maximum concentration required for the stimulation of guanylate 
cyclase activity. Crosslinking studies with DSS however, do not indicate
7 2
,sor no effect on the resting tension, (Endoh, 1979; Watanabe & Besch, 1975). |
Rugg (1989) hypothesised that ANP-stimulated cGMP production may also |
result in a negative contractile effect on ventricular muscle. Contrary to 
this Bohm et al, (1988) have shown that ANP has no contractile action in 
the rat and hum an heart.
■i:
In conclusion, the results presented provide biochemical evidence for a |
direct action of ANP on bovine ventricular muscle. In addition, they 
provide evidence of the subtype, molecular weight and density of ANP 
receptors in the bovine ventricle. There is no doubt that the presence of 
these ANP specific receptors in the bovine ventricle present a complex 
insight as to the actions of ANP in this tissue. Further studies are required 
on the molecular biology of the ANP system to determ ine the precise 
nature of the ANP receptors present in the ventricle and to determine the 
physiological role of ANP in the heart.
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doubt that the presence of these ANP specific receptors in the bovine 
ventricle present a complex insight as to the actions of ANP in this tissue
3.7 Future Perspectives
The controversy which exists over the presence or absence of ANP 
receptors in the ventricular sarcolemma is obviously the most vital issue 
and awaits further investigation. Future experimental studies lie in the 
isolation of ANP receptors from purified myocyte preparations. This 
work should involve refining receptor binding assay techniques and the 
use of various crosslinkers under various experim ental conditions. 
Further studies are also required on the m olecular biology of the ANP 
system to determ ine the precise nature of the ANP receptors present in 
the ventricle and to determine the physiological role of ANP in the heart.
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CHAPTER 4
RESULTS AND DISCUSSION OF PARTIALLY PURIFIED RAT LIVER 
PLASMA MEMBRANE EXPERIMENTS
4.1 Introduction
As part of an on-going investigation in this laboratory to assess the effects 
of dietary salt regime on plasma [ANP], ANP-specific receptor binding 
kinetics and ANP-specific receptor gene expression in the Dahl 
hypertension resistant (Dahl-R) and Dahl hypertension sensitive (Dahl-S) 
rat, partially purified liver plasma membrane homogenates (prepared as 
described in the Materials and Methods) from male Dahl-R and Dahl-S 
rats were used to determine ANP receptor population and density. The 
effects of resistance and sensitivity  of the two rat strains to the 
developm ent of hypertension, in conjunction with a variation in dietary 
salt regime on the density ( B m a x ) /  population (ANP-C or ANP-B receptors) 
and affinity (K<j) of ANP specific receptors were assessed. At 5 weeks of 
age the Dahl-rats were all allowed free access to food of a normal salt diet 
(0.8% NaCl) and then after 10 days the rats were split into groups which 
continued on a normal diet (0.8% NaCl) and groups which were given 
access to a high-salt diet (8% NaCl). The rats were killed after a further 5 
weeks and their tissues kept at - 90 °C until required. Therefore four 
groups of rats were examined; (a) Dahl-R rats on a 0.8% NaCl diet (b), 
Dahl-R an 8% NaCl diet (c), Dahl-S rats on a 0.8% NaCl diet and (d) Dahl-S 
rats on an 8% NaCl diet. For comparitive studies partially purified liver 
p lasm a m embranes were also isolated from male W istar rat and the 
density and affinity of ANP receptors were assessed.
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4.2 Blood Pressure determ inations.
The blood pressures of a subset of male Dahl-R and Dahl-S rats from each 
group were determined as described in the Materials and Methods (see fig.
4.1, table 4.1 and table 4.2). The results obtained indicate that the systolic 
blood pressure of the resistant rats on an 8% NaCl diet, (165 ±11.4 mmHg)
(group b) was significantly higher than that of the resistant rats on a 0.8%
NaCl diet (140.8 ± 18.7 mmHg) (group a). A similar significant difference |
was also noted between the two groups of sensitive animals, (group d 
compared to group c) with significantly higher values of systolic (214.6 ±
17.6 mmHg compared to 181.5 ± 13.4 mmHg) and mean blood pressures 
(154.2 ± 1 0  mmHg compared to 133 ± 16.9 mmHg) . W hen the resistant 
and the sensitive animals on a 0.8% NaCl diet are compared, (group a and 
group c) there are significantly higher systolic, mean and diastolic blood 
pressures in the sensitive group, A similar significant response is noted 
when the resistant and the sensitive animals on an 8% NaCl diet, (group b I
and group d) are compared with significantly higher systolic, mean and 
diastolic blood pressures in the sensitive group.
4.3 Receptor-Binding Experiments
4.3.1 P^^H-ANP receptor b inding to Dahl rat liver plasma membranes. 
Competitive displacement of 50 pM [^^^Il-ANP from Dahl rat liver plasma 
membranes by ANP was carried out over a 1 h incubation period at room 
temperature. The cocktail of inhibitors present in the incubation buffer, as 
described  in the  M ateria ls and  M ethods con ta ined  0.1 pM 
phosphoramidon, (a specific inhibitor of endopeptidase 24.11) and 0.1 mM 
PMSF (a general serine protease inhibitor). Individual determinations 
were made using three separate liver membrane preparations for each of 
groups (a), (b), (c) and (d) (see fig. 4.2). Results are expressed as [125i ]-ANP 
bound  (fm ol/m g  protein) and  the results of the three separate
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Figure 4.1
Systolic, Mean and Diastolic blood pressure measurements for Dahl-R and 
Dahl-S rats on different salt diets.
The results shown, are for (a) Dahl-R rats on a 0.8% NaCl diet, (b) Dahl-R 
rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and (d) Dahl-S 
rats on an 8% NaCl diet. Data for (a) is the mean of 8 "assessments" taken 
from 3 rats on 3 occasions, data for (b) is the mean of 12 "assessments" 
taken from 3 rats on 4 occasions, data for (c) is the mean 9 "assessments" 
taken from 3 rats on 3 occasions and data for (d) is the mean of 12 
"assessments" taken from 3 rats on 4 occasions. Each blood pressure 
"assessment" is the mean of 6 to 12 individual readings taken in a series of 
consecutive measurements from one rat.
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* significantly different from Dahl-R rats on an 0.8% NaCl diet (p < 0.05)
** significantly different from Dahl-R rats on a 0.8% NaCl diet (p < 0.01)
*** significantly different from Dahl-R rats on a 0.8% NaCl diet (p < 0.001)
+ significantly different from Dahl-S rats on an 0.8% NaCl diet (p < 0.05)
++ significantly different from Dahl-S rats on an 0.8% NaCl diet (p < 0.01) 
+++ significantly different from Dahl-S rats on an 0.8% NaCl diet (p < 0.001) 
° significantly different from Dahl-R rats on an 8% NaCl diet (p < 0.001)
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Table 4.1
Mean ± SD for Systolic, M ean and Diastolic blood pressures (mmHg) of 
male Dahl-R and Dahl-S rats.
Mean ± SD
Rat Groups Systolic M ean Diastolic
a 140.8 + 18.7 106.5 +19 88.1 ± 19.1
b 165 + 11.4* 117.2 ±10.3 92.6 ± 13.6
c 181.5 + 13.4 *** 133 ± 16.9 ** 109.8 ± 22.1*
d 214.6 +17.6 +++ o 154.2 ± 10++0 123.9 ± 8  + 0
significantly different from Dahl-R rats on an 0.8% NaCl diet (p ^ 0.05) 
significantly different from Dahl-R rats on a 0.8% NaCl diet (p < 0.01) 
significantly different from Dahl-R rats on a 0.8% NaCl diet (p < 0.001)
+ significantly different from Dahl-S rats on an 0.8% NaCl diet (p < 0.05)
++ significantly different from Dahl-S rats on an 0.8% NaCl diet (p < 0.01) 
+++ significantly different from Dahl-S rats on an 0.8% NaCl diet (p < 0.001) 
o significantly different from Dahl-R rats on an 8% NaCl diet (p < 0.001)
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Table 4.2
t  values for Systolic, M ean and Diastolic blood pressures of male Dahl-R 
and Dahl-S rats after dietary salt regime.
t value
Rat Groups Systolic Mean Diastolic
a ’v’ b 3.61 * 1.635 0.617
c V  d 4.711 *** 3.603 ** 2.501 *
a 'v' c 5.45 *** 3.188 ** 2.25 *
b V  d 8,19 *** 8.92 *** 6.87***
p < 0.05 p < 0.01 p < 0.001 ***
a ’v' b f values for probability are calculated from the mean of 8 and 12 
determinations ± SD, with 18 degrees of freedom,
c V  d f values for probability are calculated from the mean of 9 and 12 
determinations ± SD, with 19 degrees of freedom.
a V  c f values for probability are calculated from the mean of 8 and 9 
determinations ± SD, with 15 degrees of freedom.
b 'v‘ d f values for probability are calculated from the m ean of 12 
determinations ± SD, with 22 degrees of freedom.
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Figure 4.2
Inhibition of [^25i]-a n P binding in  Dahl Rat Liver Plasma M embranes by
ANP.
Dose response curves for ANP displacement of [125i ]-a n P binding to rat 
liver plasma membranes (25 pg pro tein /100 pi). In each graph the results 
shown are corrected for NSB and are m ean experimental values from 
three individual membrane preparations. Experiments were conducted in 
the presence of 50 pM [^25i ]_a n P for (a) Dahl-R rats on a 0.8% NaCl diet,
(b) Dahl-R rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and 
(d) Dahl-S rats on an 8% NaCl diet. Each point is the mean of at least 9 
determ inations. Phosphoram idon and PMSF concentrations in the 
incubation buffer were 0.1 pM and 0.1 mM respectively.
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experiments were combined. Scatchard analysis of the data (see fig. 4.3) 
resulted in a linear plot for group (d) only with Kd and Bmax values of 412 
± 67 pM  and 282 ± 34.4 fm o l/m g  protein. No statistically significant 
Scatchard plot could be calculated for groups (a), (b) and (c). Results in the 
absence of unlabelled ANP also indicated low levels of [1^5i ]-a NP  binding 
(between 3 and 7 fmol [^25i ]>a N P  bound /m g  protein) in the mem brane 
fractions isolated from groups (a) and (b). To check if ANP was being 
broken down under the experimental conditions used the concentrations 
of phosphoramidon and PMSF were subsequently increased 10 - fold in 
the incubation buffer to I pM and 1 mM respectively. The previous 
experim ents w ith each g roup  of rats were repeated (see fig. 4.4). 
Com petitive displacem ent b inding  analysis revealed that [l^^Il-A N P 
specific binding in the presence of 50 pM [I25i]-ANP was increased by 2.7, 
6.2, 1.4 and 1-fold for groups (a), (b), (c) and (d) respectively (see fig. 4.5). 
Scatchard analysis of these data (see fig. 4.6) resulted in linear plots for 
groups (a), (b), (c) and (d) with Kd and Bmax values of 245 ± 80 pM and 104 
± 10 fm ol/m g protein, 258 ± 18 pM  and 120 ± 28 fm ol/m g protein, 285 ± 32 
pM and 148 ± 20 fm ol/m g protein, 288 ± 84 pM and 217 ± 40 fm ol/m g 
protein respectively (see table 4.3). Scatchard analysis revealed linear plots 
for membrane fractions from each group of rats suggesting the presence of 
only one affinity class of receptor site. The ring deleted
analogue des [QSGLG] ANP (4-23)-NH2, which has been shown to be 
specific for the ANP-C receptor was used to displace [l^^I]-ANP from rat 
liver plasma m embranes (see fig. 4.7). Results obtained showed that 
0.01 pM des-ANP was able to displace 33,6 ± 6.5%, 26.5 ± 13.1%, 26.9 ± 7.1% 
and 13.7 ± 7.5% of the total receptor sites from liver plasma membranes of 
rat groups (a), (b), (c) and (d) respectively, indicating the percentage of 
ANP-C receptors present in these membrane preparations.
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Figure 4.3
Scatchard plots of the data shown in  Figure 4.2.
In each graph the results show n are corrected for NSB and are mean 
experim ental values from three individual m em brane preparations. 
Experiments were conducted in the presence of 50 pM [125i]-aNF for (a) 
Dahl-R rats on a 0.8% NaCl diet, (b) Dahl-R rats on an 8% NaCl diet, (c) 
Dahl-S rats on a 0.8% NaCl diet and (d) Dahl-S rats on an 8% NaCl diet. 
Each point is the mean of at least 3 determinations.
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Figure 4.4
Inhib ition  of [125%]_ANP binding  in Dahl-rat liver plasm a m embranes by
ANP.
Dose response curves for ANP displacement of binding to rat
liver plasma membranes (25 pg protein/100 pi). In each graph the results 
show n are corrected for NSB and are mean experimental values from 
three individual membrane preparations. Experiments were conducted in 
the presence of 50 pM [125i]-ANP for (a) Dahl-R rats on a 0.8% NaCl diet, 
(b) Dahl-R rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and 
(d) Dahl-S rats on an 8 % NaCl diet. Each point is the mean of at least 9 
determ inations, Phosphoram idon and PMSF concentrations in the 
incubation buffer were 1 pM and 1 mM respectively.
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Figure 4.5
The effect of Phosphoram idon and PMSF on P^Sij.^NP b inding  in  Dahl 
Rat liver plasma membranes.
The results shown are corrected for NSB and are m ean experimental 
values from three individual membrane preparations. Experiments were 
conducted in the presence of 50 pM [125i]-ANP and results expressed as 
[125i]_anP bound /fm o l/m g  protein for (a) Dahl-R rats on a 0.8% NaCl 
diet, (b) Dahl-R rats on an 8 % NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet 
and (d) Dahl-S rats on an 8% NaCl diet. Each point is the mean of at least 9 
determ inations.
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Figure 4.6
Scatchard plots o£ the data shown in Figure 4.4.
The results shown, corrected for NSB are for three individual experiments 
in the presence of 50 pM 125i-anP for (a) Dahl-R rats on a 0.8% NaCl diet, 
(b) Dahl-R rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and 
(d) Dahl-S rats on an 8% NaCl diet. Each point is the mean of at least 3 
determ inations.
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Table 4.3
Com parison of the effects of Phosphoram idon and PMSF on ^^^I-ANP 
binding kinetics in  Dahl-Rat liver membranes.
The Kd and B^ax values for (a) Dahl-R rats on a 0.8% NaCl diet, (b) Dahl-R 
rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and (d) Dahl-S 
rats on an 8% NaCl diet, were calculated from Scatchard analysis. Each 
value is the mean of at least 3 experiments ± S.D.
O.lpM 0.1 mM IpM Im M
P h p h ’don PMSF P hph’don PMSF
RAT Kd Bmax Kd Bmax
GROUP (pM) (fm ol/m g) (pM) (fm ol/m g)
a NC NC 245 ± 80 104 ±10
b NC NC 258 ±18 120 ±28
c NC NC 285 ±32 148 ± 20»
d 412 ±67 282 ±34.4 288 ±84 217 ± 40**
Phph’don; Phosphoram idon
PMSF; Phenyl-methyl-sulphonyl-fluoride
NC; Not Calculated
* Dahl-S rat on 0.8% NaCl diet significantly different from Dahl-R rat on 
an equivalent diet (p < 0.05 m ean of 3 experiments ± SO)
** Dahl-S rat on an 8 % NaCl diet significantly different from Dahl-R rat 
on an equivalent diet (p < 0.05 mean of 3 experiments ± SD)
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Figure 4.7
Inhibition of [i^^Il-ANP b ind ing  in Dahl-rat liver plasm a m em branes by 
des [QSGLG] ANP (4-23) - NH2.
Dose response curves for des [QSGLG] ANP(4-23)-NH2 com petitive 
displacement of [125i]-ANP binding to rat liver plasma membranes (25 jig 
protein/100 jil). In each graph the results shown are corrected for NSB 
and are m ean experim ental values from three ind iv idual m em brane 
preparations. Experiments were conducted in the presence of 50 pM [l^Sj]- 
ANP for (a) Dahl-R rats on a 0.8% NaCl diet, (b) Dahl-R rats on an 8 % 
NaCl diet, (c) Dahl-S rats on a 0 .8 % NaCl diet and (d) Dahl-S rats on an 8% 
NaCl diet. Each point is the mean of at least 9 determinations.
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4.3.2 [125i]-anP receptor binding to W istar rat liver plasma membranes 
Displacement of 50 pM [^25i]-anP from liver plasma membranes isolated 
from  male W istar rat was m easured in tw o experiments from one 
preparation. Incubations were for 1 h at room  tem perature w ith 
increasing concentrations of AN P and in the presence of 1 pM 
phosphoram idon and 1 mM PMSF. Results are expressed as [125l]-ANP 
bound  (fm ol/m g  protein) and the resu lts of the two ind iv idual 
experiments were combined, (see fig. 4.8 a). Scatchard analysis of this data 
(see fig. 4.8 b), resulted in a linear plot with K j and Bmax values of 332 ± 79 
pM and 56 ± 8 fm ol/m g protein respectively, suggesting the presence of 
only one affinity receptor class. The ANP analogue des-ANP was then 
used as a competitve ligand to displace [^25i]>aNP from the plasm a 
membranes (see fig. 4.8c). The resulting dose response curve indicated 
that 0.1 pM des-ANP was able to displace 89% of the total receptor sites 
from W istar ra t liver plasm a m em branes, indicating that this is the 
percentage of the total receptor density of ANP-C receptors present in 
these membrane preparations.
4.4 Receptor Crosslinking Experiments.
4.4.1 p25i].ANP crosslinking to Dahl rat liver plasma membranes.
Since the binding analysis with ANP and des-ANP indicated an increased 
density of ANP receptors in the Dahl-Sensitive rat group on an 8% NaCl 
diet, crosslinking experim ents w ere carried out w ith purified plasm a 
m em branes isolated from Dahl-S rats livers. However, DSS (0.1 mM) 
proved to be unsuccessful at crosslinking [125i]-ANP to receptors in this 
preparation. The crosslinking protocol was altered several tim es to 
op tim ise  the  cond itions. A ltera tions in c lu d ed  increasing  the  
concentration of DSS to 0.5 mM and also changing the crosslinker to 
ethylene glycol bis (succinimidylsucdnate) (EGS), which is 16.1 A in length
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Figure 4.8
Results of the displacem ent of p25i]_ANP in  W istar rat liver m em brane 
preparations by ANP and des-ANP.
In each graph the results shown are corrected for NSB and are m ean 
experimental values for two individual experim ents (one m em brane 
preparation) in the presence of 50 pM [125i]-anP. (a) Dose response curve 
for ANP competitive displacement of [125i]-ANP, (b) Scatchard analysis of 
data presented in (a) and (c) dose response curve for des-ANP competitive 
displacem ent of [1^^I]-ANP. Each point is the m ean of a t least 6 
determinations for (a) and (c) and at least 3 determinations for (b).
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tas opposed to DSS w hich is 11.4 A in  length. Ethylene glycol bis 
(succinimidylsuccinate) was also used a t a concentration of 0.5 mM.
U nder all conditions tested only DSS (0.5 mM) proved to be marginally 
successful at crosslinking [125i ]-ANP to two receptors in the purified liver 
plasma membranes with molecular weights of 60 kDa and 120 kDa (see fig.
4.9). Ethylene glycol bis (succinimidylsuccinate) (0.5 mM) had a limited 
amount of success and was found only to crosslink [^25i]-aNP to a protein 
of 60 kDa molecular weight (see fig. 4.9). The efficiency of crosslinking was
iextremely low and intensity of the bands did not reflect the results from g
ANP analogue binding analysis which had  indicated the presence of a 
high density (86.3 ± 7.5%) of ANP-B receptors and a lower density (13.7 ± J
7.5%) of ANP-C receptors.
1
4,4.2 P^5i]»a n P crosslinking to Wistar rat liver plasma membranes.
Crosslinking experiments with purified plasm a membranes of Wistar rat 
liver were repeatedly unsuccessful. Initially, this was surprising since 
effective crosslinking was carried out using similar protocols in bovine 
sarcolem m al m em brane preparations w hich had a sim ilar receptor 
density to that of the Dahl rat liver membranes. The results obtained with I
purified  p lasm a m em branes of W istar ra t liver indicate tha t the 
crosslinker DSS (0.1 mM) is not suitable for the determination of receptor 
su b ty p e s  in  th is tissu e . The p h o to affin ity  c ro sslin k er N - 
hydroxysuccinimidyl-4- azidobenzoate (HSAB) was also used with these 
m em brane preparations and provided similar negative results. ^
4.5 Guanylate Cyclase Experiments, i
4.5.1 Guanylate cyclase activity in  Dahl rat liver plasma membranes.
A trial na triu re tic  pep tide-stim u la ted  dose dependent increases in ^
guanylate  cyclase activity w ere show n in purified rat liver plasm a i
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Figure 4.9
C ro ss lin k in g  of [125i ] .a N P  to D ahl-ra t liver p lasm a  m em brane
hom ogenates at room tem perature in the presence or absence of ANP
[125i ]_a n P (50 pM) was incubated with liver plasma membranes (700 pg) at 
room  tem perature, in the absence (lanes a and c) and in  the presence 
(lanes b and d) of 0.1 pM ANP. Lanes a and b are in the presence of the 
crosslinker DSS and lanes c and d are in the presence of the crosslinker 
EGS. Migration of the molecular weight standards is indicated.
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4.5.2 Guanylate cyclase activity in  Wistar rat liver plasma membranes. 
Small ANP-stimulated dose dependent increases in guanylate cyclase 
activity were shown in purified rat liver plasma membranes of the Wistar 
rat, (see fig. 4.11). Basal levels ranged from 44 to 54 pm ol cGM P/m g 
protein /m in  produced w ith stim ulated levels increasing less than 2-fold 
to 62 to 73 pmol cGM P/m g protein /m in  produced. This result indicated 
the presence of an extremely low density of ANP-B receptors with linked 
guanylate cyclase activity in Wistar rat liver.
4.6 Discussion
The blood pressure results from the four groups of Dahl rats indicated that 
Dahl-S rats on a 0.8% NaCl diet have increased systolic, mean and diastolic 
blood pressures when compared to Dahl-R rats on the same diet. Dahl-S 
rats on an 8% NaCl diet have increased systolic, mean and diastolic blood
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membranes of rat groups (a), (b), (c) and (d) (see fig. 4.10). The assay was 
carried out as described in the Materials and Methods. Basal and ANP 
stimulated guanylate cyclase activities were compared for each group of #
rats (see tables 4.4, 4.5 and 4.6). These results indicated that groups (a), (b) 
and (c) had similar basal guanylate cyclase activities with values of 22 ± 4,
17 ± 5 and 27 ± 5 pmol cGM P/m g protein/m in produced respectively. The 
Dahl-S rats on an 8% NaCl diet, (group d) had a significantly higher basal I
value of 44 ± 10 pm ol cG M P/m g protein /m in  produced than all other 
three groups. The half m axim um  values required  for stim ulated I
guanylate cyclase activity for rat groups (a), (b), (c) and (d) were 3.16 ± 2.04 
nM, 2.33 ± 0.47 nM, 2.9 ± 0.71 nM and 7.33 ± 2.05 nM respectively, (see 
tables 4.4 and 4.6). The Dahl-S rats on a high salt diet, (group d) had a 
significantly higher EC50 value than Dahl-R rats on an 8 % NaCl diet 
(group b) and Dahl-S rats on a 0.8% NaCl diet (group c). 1
4
f
Figure 4.10
ANP stim ulated cGMP production in  Dahl-rat liver membranes.
Liver m em branes (10 pg) were incubated at 37 °C  for 20 m in w ith 
increasing concentrations of ANP as described in the M aterials and 
Methods. The results shown indicate ANP-stimulated guanylate cyclase 
activities in membranes isolated from (a) Dahl-R rats on a 0.8% NaCl diet, 
(b) Dahl-R rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and 
(d) Dahl-S rats on an 8% NaCl diet. Each point represents the mean ± S.D. 
of eighteen individual m easurem ents taken from three separate liver 
preparations.
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Table 4.4
Comparison of basal and ANP-stimulated cGMP production in male Dahl- 
R and Dahl-S rat liver membranes.
Basal and ANP-stimulated guanylate cyclase activities were calculated for 
liver membranes isolated from (a) Dahl-R rats on a 0.8% NaCl diet, (b) 
Dahl-R rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet and (d) 
Dahl-S rats on an 8% NaCl diet. Each experimental value is the mean of 3 
three separate liver preparations ± S.D.
pmol cGMP/mg protein/m in
Rat Group Basal IpM  ANP Fold increase 
on basal
a 22± 4 83 ± 8 3.8
b 17±5 101 ± 10 6.15
c 27±5 119 ± 20* 4.49
d 44 ± 10** (*) 245 ± 24*** + 5.6
* significantly different from Dahl-R rats on a 0.8% NaCl diet (p < 0.05 
mean of 3 experiments ± SD)
St* significantly different from Dahl-R rats on an 8% NaCl diet (p < 0.02 
mean of 3 experiments ± SD)
*** significantly different from Dahl-S rats on a 0 .8% NaCl diet (p < 0.01 
mean of 3 experiments ± SD)
+ significantly different from Dahl-R rats on an 8 % NaCl diet (p ^ 0.001 
mean of 3 experiments ± SD)
Figure 4.11
Production of cGMP in  Wistar rat liver m embranes by ANP.
Liver m em branes (10 jig) were incubated at 37 for 20 m in w ith 
increasing concentrations of ANP. Each point represents the mean ± S.D. 
of tw elve in d iv id u a l m easurem ents taken  from  tw o in d iv id u a l 
experiments from a single membrane preparation. i
pmol cGMP/mg/min
80-1
60 -
40 -
20 -
“ 12  ”11 “ 10 9 8 “ 7 6
log ANP (M)
à
%-:1
Tablets
Comparison of the concentration required for half maximal stimulation 
(EC50) of cGMP production and the Kd values for P^Sij-aNP specific 
binding.
%
EC50 values were calculated for cGMP production and [I^Sij-anp specific 
binding in liver membranes isolated from (a) Dahl-R rats on a 0.8% NaCl 
diet, (b) Dahl-R rats on an 8% NaCl diet, (c) Dahl-S rats on a 0.8% NaCl diet 
and (d) Dahl-S rats on an 8% NaCl diet.
RAT
GROUP
ECsocGMP
(nM)
Kd
(pM)
a 3.16 + 2.04 245 ±80
b 2.33 ± 0.47 258 ±18
c 2.9 ±0.71 285 ±32
d 7,33 ± 2.05* + 288 ±84
* significantly different from the EC50 value of Dahl-S rats on a 0.8% NaCl 
diet (p ^ 0.05 mean of 3 experiments ± SD)
+ significantly different from the EC50 value of Dahl-R rats on an 8% NaCl 
diet (p < 0.05 mean of 3 experiments ± SD)
Table 4.6
t  values for kinetic constants obtained for ANP binding and activation of 
guanylate cyclase in  liver m em branes isolated from m ale Dahl-R and 
Dahl-S rats.
p < 0.05 p < 0.02 p < 0.01 p <  0.001
1
I
t value 1
Rat Kd Bmax ECso Basal A N P-stim ’d
Groups guanylate guanylate max.guanylate 1
cyclase activity cyclase activity cyclase activity
a 'v' b 0.27 0.932 0.74 1.352 2.434
c V  d 0.058 2.67 2 .86* 2.63* 6.986***
a V’ c 0.764 3.4* 0.237 1.352 2.894*
b V  d 0.604 3.44* 3.368* 4.183** 9.593****
I
These t values for probability  are calculated from the m ean of 3 
experiments ± SD, with 4 degrees of freedom.
pressures when compared to Dahl-S and Dahl-R rats on a 0.8% and an 8% 
NaCl diet respectively. These results are in agreement with Snajdar & 
Rapp (1985) where differences in  blood pressures were noted between 
Dahl-S and Dahl-R rats, how ever alterations in salt diet from, norm al 
(1%) to low (0.3%) or high (8%) NaCl induced no change in blood pressure 
in the Dahl-S rats used in the study. The results presented are also in 
agreem ent with both Gutkwoska et al. (1986) and Schwartz et al. (1986) 
who reported that Dahl-S rats fed for 5 weeks on an 8% NaCl diet had 
increased blood pressure compared to Dahl-R rats on the same diet.
Results from [125i ]-ANP b ind ing  studies carried ou t w ith different 
phosphoram idon and PMSF concentrations indicated that 0.1 pM 
phosphoram idon and 0.1 mM  PMSF were not sufficient to prevent the 
enzymatic degradation of ANP in groups (a) and (b) (the Dahl-R rats) and 
resulted in low levels (3 to 7 fmol [I25i]-ANP bound/m g protein) of 
ANP-specific binding. H ow ever increasing the inhibitor concentrations 
10-fold to 1 pM phosphoram idon and 1 mM PMSF increased [I25i]-ANP- 
specific binding by 2.7 and 6.2-fold for groups (a) and (b) respectively and by
1.4 and 1-fold for groups (c) and (d) respectively. These results suggested 
that there maybe low concentrations of an ANP peptidase in groups (c) 
and (d) the Dahl-S rats and higher concentrations in groups (a) and (b) the 
Dahl-R rats. The increased concentrations of phosphoramidon and PMSF 
w ith groups (a) and (b) therefore were more effective at inhibiting the 
elevated peptidase activity, w ith  the result of increased [i25i]_ANP receptor 
binding. (This observation is how ever only speculative and further 
experim ental analysis on the  relative concentrations of ANP peptidase 
activity in each group of ra ts is required). Results from the des-ANP 
binding  analysis indicate th a t approxim ately 13-34% of the total ANP 
receptor numbers in each group of Dahl rat liver membranes were ANP-C
8 0
receptors (Bmax of approximately 34.3 ± 3.3 fm ol/m g, 31.8 ± 7.6 fm ol/m g,
40 ± 5.4 fm ol/m g and 30 ± 5.5 fm ol/m g for groups (a), (b), (c) and (d) 1|
respectively). These results suggest that the majority (67-86%), (Bmax of 
approximately 69.7 ± 3.3 fm ol/m g, 88.2 ± 7.6 fm ol/m g, 108 ± 5.4 fm ol/m g 
and 187 ± 5.5 fm ol/m g for groups (a), (b), (c) and (d) respectively) of the 
receptor sites in Dahl-S and Dahl-R rat liver plasma membranes are ANP- 
B receptors and that group (d), the sensitive rats on an 8 % NaCl diet, 
possess an increased density of ANP-B receptors (with no change in |
affinity) when compared to the other three groups. Group (d) also has a 
significantly (p < 0.05) reduced density of ANP-C receptors when compared 
to group (c) the sensitive rats on a 0.8% NaCl diet. Unfortunately 
crosslinking experim ents w ere unable to confirm these indications. IDisuccinimydyl suberate (DSS) (0.1 mM) was unable to covalently attach |
[125i]_anP to any receptor subtypes in liver membranes. However, DSS 
(0.5 mM) proved to be marginally successful at crosslinking [125i]>anP to 
two receptors (with molecular weights of 60 kDa and 120 kDa) in purified 
liver plasma membranes isolated from Dahl-S rats. Ethylene glycol bis 
(succinimidylsuccinate) (EGS) at a concentration of 0.5 mM had a limited 
amount of success and was found only to covalently attach [125%].ANP to a 
protein of 60 kDa molecular weight. These results are perhaps due to the 
low efficiency of crosslinking to receptors in this tissue compared to that %
found in bovine ventricular sarcolemmal membrane preparations. The 
reason for this difference in crosslinking efficiency betw een the two 
m embrane preparations remains unknown.
Results from  guanylate  cyclase experiments do indicate that liver
m embranes from sensitive rats on an 8% NaCl diet, (group d) have a %
Isignificantly higher basal guanylate cyclase activity w hen compared to |%m embranes isolated from all other groups. ANP-stimulated guanylate |
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cyclase activity is significantly higher in m embranes isolated from 
sensitive rats on a 0.8% N aCl d iet (group c), when com pared to I
membranes isolated from resistant rats on the same diet (group a). In 
addition ANP-stimulated guanylate cyclase activity is significantly higher |
in membranes isolated from sensitive rats on an 8% NaCl diet, (group d) 
w hen compared to m em branes isolated from sensitive rats on a 0 .8%
NaCl diet (group c) and membranes isolated from resistant rats on an 8%
NaCl diet (group b). These results are in agreement with the results from 
the radio-receptor assay and suggest an increase in the population of ANP- 
B receptors w ith associated guanylate cyclase activity in m em branes "g
isolated from sensitive anim als and m ore specifically from sensitive |
animals on an 8% NaCl diet. There is a poor correlation between ANP 
ligand binding and the subsequent stimulation of guanylate cyclase. The 
Kd values obtained for ANP ligand b inding  were found to be 
approximately 14, 9,1 1  and 23-fold lower than the EC50 values required for 
ANP stimulated activation of guanylate cyclase for rat groups (a), (b), (c) 
and (d) respectively. These results, like the results found with bovine
8 2
4:ventricular m em brane preparations suggest a complex relationship  |
'ibetween ANP ligand binding and the subsequent activation of guanylate y
cyclase.
Radio-receptor binding analysis of Wistar rat liver membranes indicated 
the presence of lower numbers of ANP-spedfic receptors than that found 
in any of the Dahl rat preparations. Results also indicated that the 
m ajority (greater than 90%) of receptors present in W istar ra t liver 
membranes were most likely ANP-C receptors. This result is contrary to 
the results obtained with the Dahl rats.
a
Experiments described demonstrate the presence of [i25i]-ANP receptors in |■ X
partially purified plasm a membrane preparations of whole rat liver. In |
addition, ANP-stimulated guanylate cyclase activity in liver membrane |
■ 5preparations was dem onstra ted . Results obtained also provide 
biochemical evidence for the presence of at least two ANP-specific %
receptors in the rat liver. ANP-specific receptors were identified as having 4
sim ilar m olecular w eights and biochemical characteristics as ANP 
receptors identified in other tissues and cells, (see section 1.2.2). Receptor
.- r
binding/crosslinking and guanylate cyclase results are in agreement with |
Yip et al (1989), where an ANP-specific receptor protein (140 kDa) in rat 
liver plasma m embranes was identified and with W aldman et a l (1984) 4
w ho show ed guany la te  cyclase activity  in ra t liver m em brane 
preparations. However these results disagree w ith Wilcox et ah (1991) 
who utilised the technique of in situ hybridisation and were unable to
■■. 'X
identify ANP-specific (ANP-BRl, ANP-BR2 and ANP-C receptor) mRNA 
in rhesus monkey liver tissue.
I
The results described show a difference in receptor population between JIWistar rat liver and Dahl rat liver. This would suggest that there is a 
genetic difference between these two rat models with regards to their ANP 
receptor populations in the liver. The physiological significance of ANP-B i
receptors in the Dahl rat liver, ANP-C receptors in the Wistar rat liver and 
the lack of ANP-specific mRNA expression in the rhesus monkey liver 
(Wilcox et a l 1991) remains to be elucidated.
The pathogenesis of sodium  retention in hepatic cirrhosis has not been 
fully explained. The discovery of ANP invited speculation that a 
deficiency in the release of ANP or resistance to its actions in the cirrhotic astate may occur (Warner et a l  1989). Epstein & Loutzenhiser (1989) have
:
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suggested that the sodium  retention associated with hepatic cirrhosis may 
be related in part to a reduced renal responsiveness to ANP and not to 
reduced ANP levels or to altered molecular species of ANP. The results 
presented here indicate the presence of specific ANP receptors in whole rat 
liver and also alterations in receptor numbers with a hypertensive state. It 
could therefore be hypothesised that there may be alterations in specific 
ANP receptor numbers in hepatic cirrhosis, in addition to a reduced renal 
responsiveness to ANP. Further experimental analysis is required to 
support this hypothesis.
In conclusion, the results presented in this thesis show, increased blood 
pressure, increased ANP-B receptor density and reduced ANP-C receptor 
density in the Dahl-S ra t whole liver, with an 8 % NaCl diet-induced 
hypertensive state. The role that this increase in ANP-B receptor density 
and reduction in ANP-C receptor density, in whole liver tissue plays in 
hypertension remains to be fully established. Recently, Kato et ah (1991) 
have shown in the bovine pulm onary artery endothelial cell line that an 
increase in intracellular cGMP resulting from activation of guanylate 
cyclase in the ANP-B receptor may cause the preferential down-regulation 
of the ANP-C receptor. This effect may regulate the rate of clearance of 
ANP from the circulation. Therefore it could be hypothesised that the 
increase in ANP-B receptors w ith ANP-specific b inding  resulting in 
increased guanylate cyclase activity and subsequent cGMP production, 
leads ultim ately to increased vasorelaxtion and the possibility of 
decreasing BP and also to a down regulation of the ANP-C receptor 
popu lation  thus reducing  the  ra te  of clearance of ANP from  the 
circulation. In parallel w ith this could be a decrease in ANP peptidase 
activity which in tu rn  w ould  m ean reduced enzymatic degradation of 
ANP, thus enabling circulatory ANP concentrations to rem ain elevated
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and able to bind to the increased ANP-B receptor population. This 
hypothesis does not explain w hy BP is highest in these Dahl-S rats. 
However, it is possible that BP w ould be even higher w ithout the 
adjustments mentioned. Recent results from this laboratory (Adam et al. 
1991 unpublished) have shown that plasma [ANP] in the Dahl-S rats used 
in this study (n = 3) are significantly (p < 0.1) increased (65.8 ± 17 fm ol/m l 
and 59.3 ± 20 fm ol/ml) when compared to Dahl-R rats (44.9 ± 16.4 and 38.4 
± 4.8 fm ol/m l) on 0.8% and 8% NaCl diets respectively. These results are 
in agreement with Schwartz et al. (1986) and Gutkwoska et al. (1986) who 
investigated the effects of salt diet on BP and plasma [ANP] in Dahl rats. 
Both of these groups reported that Dahl-S rats fed on a high salt diet, (5 
weeks on 8% salt) have a higher blood pressure and higher plasma [ANP] 
than Dahl-R rats, on the same diet. However these results are not in 
complete agreement with Snajdar & Rapp (1986) (see section 1.4.3.2). This 
group investigated Dahl-S and Dahl-R rats (2 month of age) on a normal 
(0.8%) salt diet and showed small differences in BP with no statistical 
differences in plasma [ANP]. In contrast to this, 6 month old Dahl-S rats 
showed increased BP and increased plasm a [ANP] when com pared to 
Dahl-R rats. Snajdar & Rapp (1986) also showed that changes of a similar 
order could be induced in young, 6 week old Dahl-S fed on a high (8%) salt 
diet for 3 weeks, compared to age-matched Dahl-R rats on the same diet. It 
w ould  seem therefore that age and salt d iet are both im portan t 
determinants of increased plasma [ANP] and increased BP. Results from 
the Dahl rats (10 weeks old) used in this study perhaps only reflect a salt- 
induced rather than an age-induced increase in plasma [ANP] in the 
hypertensive state. It should also be noted that plasma [ANP]'s reported 
by Snajdar & Rapp (1986) for rats (2 m onths of age) expressed as p g /  ml, 
ranging from 222 ± 22.2 pg /m l to 1079 ± 259.3 p g /m l (72.5 ± 7.25 fm ol/m l 
to 352.3 ± 84.7 fm ol/m l) are higher when compared to the results (ranging
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from 38.4 ± 4.8 fm ol/m l to 65.8 ± 17 fm ol/m l) obtained in this laboratory I
for 10 week old rats. This discrepancy is perhaps due to differences in ï|
plasma sample collection a n d /o r  the radioimmunoassay protocol utilised.
In 1989, Onwhochei and Rapp (1989) showed a deficiency in the ANP 
secretory m echanism  of pre-hypertensive Dahl-S rats resu lting  in |
increased BP and decreased plasma [ANP]. It is possible that there is such a 
deficient mechanism present in the Dahl-S rats used in this study which at 
an early stage m aintains the increase in BP and contributes to the 
hypertensive state. However the Dahl-S rats (10 week old) used in this 
study showed no indications of such defective mechanism, in that plasma 
[ANP] were increased com pared to Dahl-R rats. Therefore, in the j
hypertensive state the Dahl-S rat has increased liver ANP-B receptors, 
decreased liver ANP-C receptors, increased plasma [ANP] and possibly a 
reduced ANP peptidase activity in the liver to counteract hypertension.
The contribution of data from  additional ANP-specific experim ents in |
other Dahl rat tissues is necessary before the significance of the results of 41
the Dahl rat liver can be fully interpreted. It is possible that hypertension 
in the Dahl rat induces both positive and negative (with regards to 
counteracting hypertension) alterations in ANP binding characteristics in 
various tissues. Further experim ental studies (in various tissues) are 
being carried  out in th is labora to ry  to investigate, the b ind ing  
characteristics of ANP and ANP receptor subtypes associated w ith the 
development of hypertension in the Dahl rat.
4.7 Summary
The above radio-receptor binding data indicate, that in plasma membranes 
isolated from Dahl rat liver the presence of two ANP-specific receptor 
subtypes. In this rat strain the ANP-C receptor is in the m inority (less 
than 30% of the total ANP receptor population) and the ANP-B receptor is 4
8 6 3
in the majority. In the Dahl-S which is predisposed to the development of 
hypertension induced by a high salt diet shows an increase in blood 
pressure when fed on a norm al (0.8% NaCl) diet, when compared to the 
Dahl-R rat on an equivalent diet. Access to a high salt dietary regime (8% 
NaCl) in the Dahl-S ra t augments this condition. Analysis of receptor 
subtype in sensitive rats on an 8% NaCl diet indicate that ANP-B receptor 
density is higher than in the other three groups of rats, with increases in 
both basal and ANP stimulated guanylate cyclase activity. The indications 
from  the studies in partially  purified plasm a m em brane fractions of 
Wistar rat liver are of the presence of low densities of two ANP specific 
receptor subtypes. The ANP-B receptor being in the m inority (less than 
10% of the total receptor density) and the ANP-C receptor being in the 
majority. This is in direct contrast to the results found with the Dahl-rats. 
The precise physiological significance of ANP-B and ANP-C receptors in 
the Dahl and the the W istar rat liver remains to be elucidated.
4.8 Future Perspectives
Atrial natriuretic peptide radioreceptor assays on isolated liver cell types 
such as hepatocytes, Kuppfer cells and pit cells would provide further 
information as to the precise location of ANP receptors in the liver. From 
the results presented ANP may play a regulatory role, perhaps in lipid and 
protein synthesis in the liver however this awaits investigation. Future 
experimental studies lie in refining receptor crosslinking assay techniques 
by expanding the range of crosslinkers and the experimental conditions 
utilised. Experimental studies on specific ANP peptidase concentrations 
in the liver also await investigation. Further studies are also required on 
the molecular biology of the ANP system to determine the precise nature 
of the ANP receptors p resent in the liver and to determ ine the 
physiological role of ANP in the liver.
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